array:24 [
  "pii" => "S0001731015001477"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2015.02.008"
  "estado" => "S300"
  "fechaPublicacion" => "2015-09-01"
  "aid" => "1153"
  "copyright" => "Elsevier España, S.L.U. y AEDV"
  "copyrightAnyo" => "2014"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "crp"
  "cita" => "Actas Dermosifiliogr. 2015;106:e33-9"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 863
    "formatos" => array:3 [
      "EPUB" => 2
      "HTML" => 497
      "PDF" => 364
    ]
  ]
  "Traduccion" => array:1 [
    "en" => array:18 [
      "pii" => "S1578219015001705"
      "issn" => "15782190"
      "doi" => "10.1016/j.adengl.2015.06.005"
      "estado" => "S300"
      "fechaPublicacion" => "2015-09-01"
      "aid" => "1153"
      "copyright" => "Elsevier España, S.L.U. and AEDV"
      "documento" => "simple-article"
      "subdocumento" => "crp"
      "cita" => "Actas Dermosifiliogr. 2015;106:e33-9"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 956
        "formatos" => array:3 [
          "EPUB" => 54
          "HTML" => 578
          "PDF" => 324
        ]
      ]
      "en" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">e-Case Report</span>"
        "titulo" => "Treatment of S&#233;zary Syndrome With Alemtuzumab&#58; A Series of 5 Cases and a Review of the Literature"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:2 [
          0 => "en"
          1 => "es"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "e33"
            "paginaFinal" => "e39"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Tratamiento del s&#237;ndrome de S&#233;zary con alemtuzumab&#58; serie de 5 casos y revisi&#243;n de la literatura"
          ]
        ]
        "contieneResumen" => array:2 [
          "en" => true
          "es" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figure 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 538
                "Ancho" => 1500
                "Tamanyo" => 162726
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">A&#44; Erythematous lesions on the abdomen of a patient with SS before starting treatment with alemtuzumab &#40;case<span class="elsevierStyleHsp" style=""></span>3&#41;&#46; B&#44; In the same patient&#44; resolution of the erythema 4 weeks after starting treatment with alemtuzumab&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "E&#46; del Alc&#225;zar-Viladomiu, A&#46; Tuneu-Valls, A&#46; L&#243;pez-Pesta&#241;a, M&#46;J&#46; Vidal-Mance&#241;ido"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "del Alc&#225;zar-Viladomiu"
              ]
              1 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Tuneu-Valls"
              ]
              2 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "L&#243;pez-Pesta&#241;a"
              ]
              3 => array:2 [
                "nombre" => "M&#46;J&#46;"
                "apellidos" => "Vidal-Mance&#241;ido"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "es" => array:9 [
          "pii" => "S0001731015001477"
          "doi" => "10.1016/j.ad.2015.02.008"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "es"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731015001477?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219015001705?idApp=UINPBA000044"
      "url" => "/15782190/0000010600000007/v1_201508271313/S1578219015001705/v1_201508271313/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S0001731015001258"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2015.01.013"
    "estado" => "S300"
    "fechaPublicacion" => "2015-09-01"
    "aid" => "1141"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; y AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "cor"
    "cita" => "Actas Dermosifiliogr. 2015;106:579-80"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 695
      "formatos" => array:3 [
        "EPUB" => 3
        "HTML" => 377
        "PDF" => 315
      ]
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Casos para el diagn&#243;stico</span>"
      "titulo" => "N&#243;dulos frontales asociados a adenopat&#237;as generalizadas"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "579"
          "paginaFinal" => "580"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Nodules on the Forehead Associated With Generalized Lymphadenopathy"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:6 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 921
              "Ancho" => 950
              "Tamanyo" => 184550
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A&#46; Lobato-Berezo, F&#46; Burgos-L&#225;zaro, M&#46;&#193;&#46; Gallego-Vald&#233;s"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Lobato-Berezo"
            ]
            1 => array:2 [
              "nombre" => "F&#46;"
              "apellidos" => "Burgos-L&#225;zaro"
            ]
            2 => array:2 [
              "nombre" => "M&#46;&#193;&#46;"
              "apellidos" => "Gallego-Vald&#233;s"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1578219015001729"
        "doi" => "10.1016/j.adengl.2015.06.007"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219015001729?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731015001258?idApp=UINPBA000044"
    "url" => "/00017310/0000010600000007/v1_201509041239/S0001731015001258/v1_201509041239/es/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S0001731015001416"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2015.02.003"
    "estado" => "S300"
    "fechaPublicacion" => "2015-09-01"
    "aid" => "1147"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2015;106:569-77"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 995
      "formatos" => array:3 [
        "EPUB" => 2
        "HTML" => 602
        "PDF" => 391
      ]
    ]
    "es" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original</span>"
      "titulo" => "Modificaci&#243;n de la dosis de terapias biol&#243;gicas en psoriasis moderada-grave&#58; an&#225;lisis descriptivo en condiciones de pr&#225;ctica cl&#237;nica"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "569"
          "paginaFinal" => "577"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis&#58; A Descriptive Analysis in a Clinical Practice Setting"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1492
              "Ancho" => 2655
              "Tamanyo" => 172383
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Algoritmo del tratamiento seguido en el estudio&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "O&#46; Baniandr&#233;s, V&#46;J&#46; Rodr&#237;guez-Soria, R&#46;M&#46; Romero-Jim&#233;nez, R&#46; Su&#225;rez"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "O&#46;"
              "apellidos" => "Baniandr&#233;s"
            ]
            1 => array:2 [
              "nombre" => "V&#46;J&#46;"
              "apellidos" => "Rodr&#237;guez-Soria"
            ]
            2 => array:2 [
              "nombre" => "R&#46;M&#46;"
              "apellidos" => "Romero-Jim&#233;nez"
            ]
            3 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Su&#225;rez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1578219015001699"
        "doi" => "10.1016/j.adengl.2015.06.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219015001699?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731015001416?idApp=UINPBA000044"
    "url" => "/00017310/0000010600000007/v1_201509041239/S0001731015001416/v1_201509041239/es/main.assets"
  ]
  "es" => array:17 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">e-Casos cl&#237;nicos</span>"
    "titulo" => "Tratamiento del s&#237;ndrome de S&#233;zary con alemtuzumab&#58; serie de 5 casos y revisi&#243;n de la literatura"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "e33"
        "paginaFinal" => "e39"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "E&#46; del Alc&#225;zar-Viladomiu, A&#46; Tuneu-Valls, A&#46; L&#243;pez-Pesta&#241;a, M&#46;J&#46; Vidal-Mance&#241;ido"
        "autores" => array:4 [
          0 => array:4 [
            "nombre" => "E&#46;"
            "apellidos" => "del Alc&#225;zar-Viladomiu"
            "email" => array:1 [
              0 => "elenadelalcazarviladomiu&#64;gmail&#46;com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "Tuneu-Valls"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "L&#243;pez-Pesta&#241;a"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "M&#46;J&#46;"
            "apellidos" => "Vidal-Mance&#241;ido"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario Donostia&#44; San Sebasti&#225;n&#44; Espa&#241;a"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a&#44; Hospital Universitario Donostia&#44; San Sebasti&#225;n&#44; Espa&#241;a"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Treatment of S&#233;zary Syndrome With Alemtuzumab&#58; A Series of 5 Cases and a Review of the Literature"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 538
            "Ancho" => 1500
            "Tamanyo" => 145000
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">A&#46; Lesiones eritematosas en el abdomen de una paciente con SS antes de iniciar el tratamiento con alemtuzumab &#40;caso 3&#41;&#46; B&#46; Desaparici&#243;n del eritema a las 4 semanas de iniciar el tratamiento con alemtuzumab &#40;caso 3&#41;&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introducci&#243;n</span><p id="par0005" class="elsevierStylePara elsevierViewall">El s&#237;ndrome de S&#233;zary &#40;SS&#41; es una entidad infrecuente que representa aproximadamente el 3&#37; de todos los linfomas cut&#225;neos de c&#233;lulas T&#46; Se considera una variante agresiva que se caracteriza por la presencia de eritrodermia&#44; linfocitos T at&#237;picos circulantes &#40;c&#233;lulas de S&#233;zary&#41; con o sin adenopat&#237;as<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">1</span></a>&#46; Se clasifica como un T4&#44; N0-3&#44; M0-1&#44; B2 seg&#250;n la <span class="elsevierStyleItalic">International Society for Cutaneous Lymphomas</span> &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#41;<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">1&#8211;3</span></a>&#46; El prurito es el s&#237;ntoma principal y puede llegar a tener un gran impacto en la calidad de vida&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0010" class="elsevierStylePara elsevierViewall">El pron&#243;stico es pobre&#44; con una supervivencia del 24&#37; a los 5 a&#241;os&#44; con pocas respuestas y remisiones duraderas tras los tratamientos<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">4</span></a>&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Para su tratamiento son necesarias terapias sist&#233;micas&#44; ya que las dirigidas exclusivamente a la piel son insuficientes&#46; La elecci&#243;n viene determinada por la extensi&#243;n de la enfermedad&#44; el impacto en la calidad de vida&#44; la edad y las comorbilidades del paciente&#46; Aunque existen diferentes tipos de tratamiento para el SS &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a>&#41;<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">3</span></a>&#44; hay pocos estudios sobre su eficacia&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">En los &#250;ltimos a&#241;os han aparecido nuevas terap&#233;uticas&#44; entre las que encontramos las terapias biol&#243;gicas&#46; El alemtuzumab es un anticuerpo monoclonal humanizado dirigido contra la glucoprote&#237;na CD52 que se expresa en la superficie de los linfocitos T y B&#44; c&#233;lulas <span class="elsevierStyleItalic">natural killer</span>&#44; monocitos y macr&#243;fagos&#44; consiguiendo su depleci&#243;n en sangre perif&#233;rica<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">3&#44;5</span></a>&#46; Se cree que act&#250;a por lisis celular directa mediada por neutr&#243;filos&#44; complemento y citotoxicidad dependiente de anticuerpos y apoptosis<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">3&#8211;6</span></a>&#46; En el a&#241;o 2001 se aprob&#243; su uso para el tratamiento de la leucemia linf&#225;tica cr&#243;nica B&#44; aunque algunos autores lo han utilizado en casos refractarios de SS y MF en estadio avanzado&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Casos cl&#237;nicos</span><p id="par0025" class="elsevierStylePara elsevierViewall">Presentamos 5 pacientes &#40;3 mujeres y 2 hombres&#41; diagnosticados de SS estadio IVA<span class="elsevierStyleInf">1</span> &#40;T4&#44; N0&#44; M0&#44; B2&#41; tratados con alemtuzumab desde el a&#241;o 2008 hasta el 2012&#46; Cuatro hab&#237;an realizado tratamientos previos &#40;fototerapia&#44; prednisona&#44; metotrexato&#44; gemcitabina y bexaroteno&#41;&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Respecto al tratamiento con alemtuzumab hemos recogido las siguientes variables &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;&#58; 1&#41; duraci&#243;n&#59; 2&#41; tipo de respuesta&#59; 3&#41; tiempo transcurrido hasta el inicio de la respuesta&#59; 4&#41; duraci&#243;n de la misma tras la suspensi&#243;n del tratamiento&#59; y 5&#41; las c&#233;lulas de S&#233;zary en sangre perif&#233;rica&#46; Adem&#225;s&#44; hemos analizado la evoluci&#243;n&#44; el tiempo de seguimiento y las complicaciones asociadas al alemtuzumab&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">Hemos clasificado el tipo de respuesta de la siguiente manera&#58; completa &#40;RC&#41;&#44; parcial &#40;RP&#41; o progresi&#243;n de la enfermedad &#40;PE&#41;&#44; bas&#225;ndonos en el trabajo de Olsen et al&#46;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">2</span></a> &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0040" class="elsevierStylePara elsevierViewall">La pauta utilizada fue la administraci&#243;n subcut&#225;nea de una primera dosis inicial de 3<span class="elsevierStyleHsp" style=""></span>mg y posteriormente 10<span class="elsevierStyleHsp" style=""></span>mg 3 veces por semana&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">Los 5 pacientes recibieron profilaxis oral para <span class="elsevierStyleItalic">Pneumocystis jiroveci</span> con sulfametoxazol-trimetroprim&#44; aciclovir para herpes y fluconazol para <span class="elsevierStyleItalic">Candida</span>&#46; Para la profilaxis de citomegalovirus &#40;CMV&#41; se realiz&#243; carga viral semanal&#44; utilizando tratamiento anticipatorio con valganciclovir oral en los casos de reactivaci&#243;n&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">En cuanto a los resultados se obtuvo respuesta en 4 de 5 pacientes &#40;tasa de respuesta global del 80&#37;&#41;&#58; 2 RP &#40;40&#37;&#41; y 2 RC &#40;40&#37;&#41;&#46; La mediana de duraci&#243;n del tratamiento fue de 8 semanas &#40;4-13&#41; y la mediana de duraci&#243;n de la respuesta tras suspender el tratamiento de 13 meses &#40;5-66&#41;&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">Como complicaciones un paciente present&#243; una neumon&#237;a neumoc&#243;cica&#44; 3 un s&#237;ndrome de liberaci&#243;n de citocinas y tuvimos 2 casos de reactivaciones subcl&#237;nicas de CMV&#46; No tuvimos ning&#250;n caso de complicaci&#243;n hematol&#243;gica&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">La mediana de seguimiento fue de 27 meses &#40;23-67&#41; tras el inicio del tratamiento&#46; Un paciente falleci&#243; a los 24 meses por una transformaci&#243;n a un linfoma no Hodgkin de alto grado&#46; Actualmente&#44; 3 pacientes est&#225;n en progresi&#243;n y una sigue en remisi&#243;n completa tras 67 meses de finalizar el tratamiento&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Discusi&#243;n</span><p id="par0065" class="elsevierStylePara elsevierViewall">El alemtuzumab se ha utilizado tanto en casos refractarios de MF en estadio avanzado como de SS&#46; La primera descripci&#243;n es de 1998 en 8 pacientes con MF<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">7</span></a>&#46; En 2003 se demostr&#243; su utilidad en un estudio en fase <span class="elsevierStyleSmallCaps">ii</span> en 22 pacientes con MF&#47;SS<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">8</span></a>&#46; Desde entonces se han publicado algunas series cortas y casos aislados&#46; En la literatura revisada hemos encontrado un total de 13 series<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">4&#44;6&#8211;17</span></a> y 6 casos aislados de MF y SS recogi&#233;ndose las primeras en la <a class="elsevierStyleCrossRef" href="#tbl0020">tabla 4</a>&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0070" class="elsevierStylePara elsevierViewall">Respecto a la respuesta tras el tratamiento&#44; en los 2 trabajos m&#225;s amplios&#44; de 22 y 39 pacientes&#44; la tasa de respuesta global fue del 55&#37; y 51&#37; respectivamente<a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">8&#44;9</span></a>&#46; La duraci&#243;n mediana de la respuesta fue de 12 meses&#44; aunque es variable seg&#250;n las distintas series<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">4&#44;6&#8211;17</span></a>&#46; En la serie de 39 casos se observ&#243; que el alemtuzumab puede inducir remisiones duraderas &#40;m&#225;s de 2 a&#241;os&#41; en el SS &#40;5 pacientes&#41;&#44; no as&#237; en los casos de MF &#40;un caso&#41;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">9</span></a>&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">La pauta de tratamiento ha variado con los a&#241;os&#46; La dosis utilizada en los primeros trabajos era v&#237;a intravenosa&#58; una primera dosis inicial de 3<span class="elsevierStyleHsp" style=""></span>mg&#44; luego 10<span class="elsevierStyleHsp" style=""></span>mg y finalmente 30<span class="elsevierStyleHsp" style=""></span>mg&#44; manteniendo esta &#250;ltima dosis 3 veces por semana<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">7&#44;8&#44;10&#8211;13</span></a>&#46; Posteriormente&#44; se observ&#243; que el alemtuzumab v&#237;a subcut&#225;nea a dosis bajas podr&#237;a ser igual de efectivo<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">4&#44;14</span></a>&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">Las infecciones y la toxicidad hematol&#243;gica son complicaciones ligadas al tratamiento&#46; La pauta de 10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a subcut&#225;nea ha demostrado una menor incidencia de estos efectos adversos<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">4&#44;14&#44;15</span></a>&#46; La infecci&#243;n oportunista m&#225;s frecuente es la reactivaci&#243;n del CMV&#44; aunque tambi&#233;n se han descrito otros tipos de infecciones<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">4</span></a>&#46; En cuanto a la toxicidad hematol&#243;gica&#44; la mielosupresi&#243;n es la m&#225;s com&#250;n<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">4</span></a>&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">El s&#237;ndrome de liberaci&#243;n de citocinas es la complicaci&#243;n m&#225;s frecuente durante la terapia<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">7&#44;8&#44;10&#44;11</span></a>&#46; Para disminuir su aparici&#243;n se realiza una escalada progresiva de la dosis&#46; <span class="elsevierStyleItalic">Lenihan</span> et al&#46; publicaron 4 casos de toxicidad card&#237;aca durante el tratamiento en pacientes previamente sanos<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">13</span></a>&#46; Dado que no se observ&#243; en ning&#250;n otro estudio&#44; se ha puesto en entredicho esta relaci&#243;n causal&#46; Recientemente se ha descrito un caso de hematofagocitosis cut&#225;nea localizada en el sitio de inyecci&#243;n del alemtuzumab en una paciente sin reactivaci&#243;n viral del Epstein-Barr<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">18</span></a>&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">En la literatura revisada el alemtuzumab se ha utilizado indistintamente tanto para la MF como para el SS&#46; De hecho&#44; la mayor&#237;a de los trabajos agrupan el SS con la MF en estadio avanzado&#46; Actualmente se considera que la MF eritrod&#233;rmica es una progresi&#243;n de la MF con ausencia o poca afectaci&#243;n hematol&#243;gica&#44; a diferencia de lo que acontece en el SS&#44; que aparece <span class="elsevierStyleItalic">de novo</span> y tiene una importante afectaci&#243;n sangu&#237;nea<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">1</span></a>&#46; En 2012 Clark et al&#46; publicaron que el alemtuzumab podr&#237;a ser eficaz solo cuando existiera afectaci&#243;n hematol&#243;gica &#40;en el SS y en casos de MF eritrod&#233;rmica con afectaci&#243;n sangu&#237;nea&#41;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">6</span></a>&#46; Estos autores postulan que ambas entidades provienen de distintos tipos de c&#233;lulas T memoria&#58; los linfocitos malignos en pacientes con SS presentar&#237;an un fenotipo de c&#233;lulas memoria central CCR7&#43;&#47;L-selectina&#43; &#40;c&#233;lulas migratorias que se encuentran circulando en la sangre&#44; en la piel y en los ganglios linf&#225;ticos&#41;&#44; mientras que los linfocitos malignos de la MF derivar&#237;an de c&#233;lulas no migratorias residentes en la piel que no circulan por la sangre&#46; El alemtuzumab deplecionar&#237;a todos los linfocitos T en la sangre&#44; pero la poblaci&#243;n de c&#233;lulas residentes en la piel escapar&#237;a del efecto del anticuerpo&#44; permaneciendo despu&#233;s del tratamiento&#46; Adem&#225;s&#44; el alemtuzumab requiere la presencia de neutr&#243;filos y c&#233;lulas <span class="elsevierStyleItalic">natural killer</span> &#40;ambas presentes en sangre y no en piel&#41; para la depleci&#243;n de linfocitos&#44; por lo que solo eliminar&#237;a las c&#233;lulas en sangre perif&#233;rica&#46; De esta forma&#44; los pacientes con SS ser&#237;an los principales candidatos para este tratamiento&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">Lamentablemente&#44; en agosto de 2012 se anul&#243; su uso para la leucemia linf&#225;tica cr&#243;nica B y otras enfermedades hematol&#243;gicas&#44; y actualmente solo est&#225; disponible para la esclerosis m&#250;ltiple&#46; Para el tratamiento en pacientes con SS solo se puede conseguir mediante acceso individualizado con protocolo&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Conclusiones</span><p id="par0100" class="elsevierStylePara elsevierViewall">Presentamos 5 casos de SS tratados con alemtuzumab con una tasa de respuesta del 80&#37;&#46; La pauta de 10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a subcut&#225;nea fue bien tolerada y la mediana de duraci&#243;n de la respuesta fue de 13 meses&#46; El alemtuzumab puede ser un f&#225;rmaco &#250;til en casos de SS refractarios a otros tratamientos&#44; con una r&#225;pida respuesta cl&#237;nica y mejor&#237;a de la calidad de vida con disminuci&#243;n o desaparici&#243;n del prurito&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Conflicto de intereses</span><p id="par0105" class="elsevierStylePara elsevierViewall">Los autores declaran no tener ning&#250;n conflicto de intereses&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Responsabilidades &#233;ticas</span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Protecci&#243;n de personas y animales</span><p id="par0110" class="elsevierStylePara elsevierViewall">Los autores declaran que para esta investigaci&#243;n no se han realizado experimentos en seres humanos ni en animales&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Confidencialidad de los datos</span><p id="par0115" class="elsevierStylePara elsevierViewall">Los autores declaran que en este art&#237;culo no aparecen datos de pacientes&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Derecho a la privacidad y consentimiento informado</span><p id="par0120" class="elsevierStylePara elsevierViewall">Los autores declaran que en este art&#237;culo no aparecen datos de pacientes&#46;</p></span></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:11 [
        0 => array:3 [
          "identificador" => "xres547424"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec565303"
          "titulo" => "Palabras clave"
        ]
        2 => array:3 [
          "identificador" => "xres547425"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec565302"
          "titulo" => "Keywords"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introducci&#243;n"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Casos cl&#237;nicos"
        ]
        6 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Discusi&#243;n"
        ]
        7 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Conclusiones"
        ]
        8 => array:2 [
          "identificador" => "sec0025"
          "titulo" => "Conflicto de intereses"
        ]
        9 => array:3 [
          "identificador" => "sec0030"
          "titulo" => "Responsabilidades &#233;ticas"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Protecci&#243;n de personas y animales"
            ]
            1 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Confidencialidad de los datos"
            ]
            2 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Derecho a la privacidad y consentimiento informado"
            ]
          ]
        ]
        10 => array:1 [
          "titulo" => "Bibliograf&#237;a"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec565303"
          "palabras" => array:3 [
            0 => "S&#237;ndrome de S&#233;zary"
            1 => "Alemtuzumab"
            2 => "Tratamiento"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec565302"
          "palabras" => array:3 [
            0 => "S&#233;zary syndrome"
            1 => "Alemtuzumab"
            2 => "Treatment"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">El alemtuzumab es un anticuerpo monoclonal que se ha utilizado como terap&#233;utica en casos refractarios de s&#237;ndrome de S&#233;zary &#40;SS&#41; y micosis fungoide en estadio avanzado&#46;</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Presentamos 5 pacientes diagnosticados de SS tratados con alemtuzumab entre los a&#241;os 2008 y 2012&#44; con una tasa de respuesta global del 80&#37; &#40;40&#37; respuestas parciales y 40&#37; respuestas completas&#41;&#46; La pauta de 10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a subcut&#225;nea fue bien tolerada y con una toxicidad aceptable&#46; En nuestra casu&#237;stica la mediana de duraci&#243;n de la respuesta fue de 13 meses&#44; sin embargo uno de los pacientes contin&#250;a en remisi&#243;n completa tras 67 meses&#44; hecho destacable dada la baja supervivencia del SS&#46;</p><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Como conclusi&#243;n&#44; creemos que el alemtuzumab es un f&#225;rmaco que podr&#237;a ser &#250;til en casos de SS refractarios a otros tratamientos&#46; Dado que no existen tratamientos curativos en el SS&#44; ser&#237;a una alternativa terap&#233;utica a tener en cuenta&#46;</p></span>"
      ]
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Alemtuzumab is a monoclonal antibody that has been used to treat refractory cases of S&#233;zary syndrome &#40;SS&#41; and advanced mycosis fungoides&#46;</p><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">We present 5 patients with SS who were treated with alemtuzumab between 2008 and 2012&#44; with an overall response rate of 80&#37; &#40;40&#37; partial response and 40&#37; complete response&#41;&#46; A regimen of 10<span class="elsevierStyleHsp" style=""></span>mg administered subcutaneously was well tolerated with acceptable toxicity&#46; The median duration of response was 13 months&#46; However&#44; one patient remains in complete remission after 67 months&#44; a remarkable outcome given the low survival rate associated with SS&#46;</p><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">In conclusion&#44; we believe that alemtuzumab may be useful in cases of SS refractory to other treatments&#46; As there are no curative treatments for SS&#44; alemtuzumab should be considered as a therapeutic option&#46;</p></span>"
      ]
    ]
    "multimedia" => array:5 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 538
            "Ancho" => 1500
            "Tamanyo" => 145000
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">A&#46; Lesiones eritematosas en el abdomen de una paciente con SS antes de iniciar el tratamiento con alemtuzumab &#40;caso 3&#41;&#46; B&#46; Desaparici&#243;n del eritema a las 4 semanas de iniciar el tratamiento con alemtuzumab &#40;caso 3&#41;&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">EORTC&#58; <span class="elsevierStyleItalic">European Organisation for Research and Treatment of Cancer</span>&#59; ISCL <span class="elsevierStyleItalic">International Society for Cutaneous Lymphomas</span>&#59; LN&#58; <span class="elsevierStyleItalic">lymph node</span>&#59; NCI&#58; <span class="elsevierStyleItalic">National Cancer Institute</span>&#59; TCR&#58; receptor de linfocito T&#46;</p><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Fuente&#58; Olsen et al&#46;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">2</span></a>&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Piel &#40;T&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>T1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">M&#225;culas limitadas&#44; p&#225;pulas y&#47;o placas cubriendo &#60;<span class="elsevierStyleHsp" style=""></span>10&#37; de la superficie cut&#225;nea&#46; T<span class="elsevierStyleInf">1a</span> &#40;solo m&#225;culas&#41; y T<span class="elsevierStyleInf">1b</span> &#40;m&#225;culas y placas&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>T2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">M&#225;culas&#44; p&#225;pulas y&#47;o placas cubriendo &#8805;<span class="elsevierStyleHsp" style=""></span>10&#37; de la superficie cut&#225;nea&#46; T<span class="elsevierStyleInf">2a</span> &#40;solo m&#225;culas&#41; y T<span class="elsevierStyleInf">2b</span> &#40;m&#225;culas y placas&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>T3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Uno o m&#225;s tumores &#40;&#62;<span class="elsevierStyleHsp" style=""></span>1<span class="elsevierStyleHsp" style=""></span>cm de di&#225;metro&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>T4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Confluencia de eritema<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>80&#37; de la superficie cut&#225;nea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Ganglios&#40;N&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>N0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No ganglios linf&#225;ticos perif&#233;ricos anormales&#44; la biopsia no es necesaria&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>N1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ganglios perif&#233;ricos cl&#237;nicamente anormales&#44; histol&#243;gicamente Dutch grado 1 o NCI LN<span class="elsevierStyleInf">0-2</span>&#46; N<span class="elsevierStyleInf">1a</span> clonalidad negativa y N<span class="elsevierStyleInf">1b</span> clonalidad positiva&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>N2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ganglios perif&#233;ricos cl&#237;nicamente anormales&#44; histol&#243;gicamente Dutch grado 2 o NCI LN<span class="elsevierStyleInf">3</span>&#46; N<span class="elsevierStyleInf">2a</span> clonalidad negativa y N<span class="elsevierStyleInf">2b</span> clonalidad positiva&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>N3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ganglios perif&#233;ricos cl&#237;nicamente anormales&#44; histol&#243;gicamente Dutch grado 3-4 o NCI LN<span class="elsevierStyleInf">4</span> clonalidad positiva o negativa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Nx&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ganglios perif&#233;ricos cl&#237;nicamente anormales sin confirmaci&#243;n histol&#243;gica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Visceral &#40;M&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>M0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No existencia de afectaci&#243;n visceral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>M1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Afectaci&#243;n visceral &#40;debe tener confirmaci&#243;n histol&#243;gica y debe especificarse el &#243;rgano&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Hematol&#243;gica &#40;B&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>B0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ausencia de afectaci&#243;n hematol&#243;gica significativa &#40;&#8804;<span class="elsevierStyleHsp" style=""></span>5&#37; de linfocitos at&#237;picos&#47;c&#233;lulas de S&#233;zary&#41;&#46; B<span class="elsevierStyleInf">0a</span> clonalidad negativa y B<span class="elsevierStyleInf">0b</span> clonalidad positiva&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>B1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Baja afectaci&#243;n hematol&#243;gica &#40;&#62;<span class="elsevierStyleHsp" style=""></span>5&#37; de linfocitos at&#237;picos&#47;c&#233;lulas de S&#233;zary&#41;&#46; B<span class="elsevierStyleInf">1a</span> clonalidad negativa y B<span class="elsevierStyleInf">1b</span> clonalidad positiva&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>B2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Alta afectaci&#243;n hematol&#243;gica definida como uno de los siguientes&#58; &#8805;<span class="elsevierStyleHsp" style=""></span>1&#46;000 c&#233;lulas de S&#233;zary&#47;&#956;l con TCR positivo&#59; CD4&#47;CD8<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 con TCR positivo&#59; o c&#233;lulas CD4&#43; CD7&#8211;<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>40&#37; o CD4&#43; CD26&#8211; &#8805;<span class="elsevierStyleHsp" style=""></span>30&#37; con TCR positivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab884196.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Clasificaci&#243;n de la micosis fungoide&#47;s&#237;ndrome de S&#233;zary propuesta por la ISCL y la EORTC</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabla 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">IFN&#58; interfer&#243;n&#59; TPMO&#58; transplante de progenitores de m&#233;dula &#243;sea&#46;</p><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Fuente&#58; modificada de Jawed et al&#46;<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">3</span></a>&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Tipo de terapia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Inmunomoduladores</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Interfer&#243;n &#40;IFN alfa e IFN gamma&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Retinoide &#40;bexaroteno&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Denileukin diftitox&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Fotof&#233;resis extracorp&#243;rea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Terapias biol&#243;gicas</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Alemtuzumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Radioterapia</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Irradiaci&#243;n corporal total con electrones <span class="elsevierStyleItalic">&#40;electron beam&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Tratamientos combinados</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IFN alfa<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>fototerapia o retinoide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Retinoide<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>fototerapia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Fotof&#233;resis extracorp&#243;rea<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>IFN alfa o retinoide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Quimioterapia sist&#233;mica</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Monoterapia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Metotrexato&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Doxorrubicina pegilada&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Poliquimioterapia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">An&#225;logos de las purinas&#47;pirimidinas &#40;fludarabina&#44; 2-clorodeoxiadenosina&#44; deoxicoformicina&#44; gemcitabina&#44; forodesina&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Agentes alquilantes &#40;clorambucilo&#44; mostaza nitrogenada&#44; ciclofosfamida&#44; temozolamida&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Inhibidores topoisomerasa &#40;etop&#243;sido&#44; doxurribicina pegilada&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Inhibidores histona deacetilasa &#40;vorinostat&#44; romidepsina&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CHOP y CHOP-<span class="elsevierStyleItalic">like</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>TPMO&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Aut&#243;logo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Alog&#233;nico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Alog&#233;nico no mieloablativo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab884197.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Tratamientos en el SS</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "tbl0015"
        "etiqueta" => "Tabla 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">H&#58; hombre&#59; LNH&#58; linfoma no Hodgkin&#59; m&#58; meses&#59; M&#58; mujer&#44; NR&#58; no respuesta&#44; PE&#58; progresi&#243;n de la enfermedad&#59; RC&#58; remisi&#243;n completa&#59; RP&#58; respuesta parcial&#44; Sd&#58; s&#237;ndrome&#59; S&#58; semanas&#59; &#40;X&#175;&#41;&#58; mediana&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Sexo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Edad&#40;a&#241;os&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Duraci&#243;ndeltratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Iniciode larespuesta&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Respuesta Cut&#225;nea<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Respuesta sangu&#237;nea<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&#40;c&#233;lulas de S&#233;zary&#47;&#956;l y &#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Respuesta global&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Duraci&#243;n de la respuesta&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Complicaciones&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Evoluci&#243;n y tiempo de seguimiento tras inicio del tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">M&#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">57&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4 S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RCPre-tto&#8594;1&#46;050 &#40;7&#37;&#41;Post-tto&#8594;0 &#40;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">66<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RC67<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">H&#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">65&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RCPre-tto&#8594;9&#46;530 &#40;32&#37;&#41;Post-tto&#8594;147 &#40;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Sd liberaci&#243;n citocinasReactivaci&#243;n CMVNeumon&#237;a neumoc&#243;cica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">&#201;xitus</span> por LNH alto grado24<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">M&#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">85&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RPPre-tto&#8594;1&#46;215 &#40;12&#37;&#41;Post-tto&#8594;379 &#40;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Retratamiento a las 4<span class="elsevierStyleHsp" style=""></span>S sin mejor&#237;a&#46;Actualmente leukeran-prednisona27<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">H&#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">75&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RCPre-tto&#8594;554 &#40;4&#37;&#41;<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a>Post-tto&#8594;0 &#40;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">15<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Sd liberaci&#243;n citocinasReactivaci&#243;n CMV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Actualmente fotof&#233;resis32<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">M&#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">57&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RCPre-tto&#8594;1&#46;342 &#40;8&#37;&#41;Post-tto&#8594;55 &#40;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Sd liberaci&#243;n citocinas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Trasplante alog&#233;nico de m&#233;dula &#243;sea20<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">&#40;X&#175;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">65&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab884195.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">RC&#58; 100&#37; del aclaramiento de las lesiones&#44; RP&#58; 50-99&#37; del aclaramiento de las lesiones iniciales sin nuevos tumores &#40;T3&#41; en pacientes con T1&#44; T2 o T4&#44; PE<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>25&#37; de incremento de la enfermedad cut&#225;nea o nuevos tumores &#40;T3&#41; en pacientes con T1&#44; T2 o T4 o p&#233;rdida de respuesta en pacientes con respuesta completa o respuesta parcial<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">2</span></a>&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">RC&#58; B<span class="elsevierStyleInf">0</span> y RP<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>50&#37; de reducci&#243;n de la carga tumoral sangu&#237;nea inicial<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">2</span></a>&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">El caso 4 presentaba &#60;<span class="elsevierStyleHsp" style=""></span>1000 c&#233;lulas de Sez&#225;ry&#44; sin embargo ten&#237;a un cociente CD4&#47;CD8<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44;por lo que se consider&#243; un estadio IVA<span class="elsevierStyleInf">1</span> como el resto&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Nuestra serie de 5 casos de SS tratados con alemtuzumab</p>"
        ]
      ]
      4 => array:7 [
        "identificador" => "tbl0020"
        "etiqueta" => "Tabla 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">CMV&#58; citomegalovirus&#59; EE&#58; enfermedad estable&#59; FOD&#58; fiebre de origen desconocido&#59; IAM&#58; infarto agudo de miocardio&#59; ICC&#58; insuficiencia card&#237;aca congestiva&#59; iv&#58; intravenosa&#59; LCCB&#58; linfoma cut&#225;neo de c&#233;lula B&#59; LCCT&#58; linfomas cut&#225;neos de c&#233;lulas T&#59; LCCT-L&#58; linfomas cut&#225;neos de c&#233;lulas T leucemizados&#59; LCT perif&#233;ricos&#58; linfomas de c&#233;lulas T perif&#233;ricos&#59; LNH&#58; linfoma no Hodgkin&#59; MRSA&#58; <span class="elsevierStyleItalic">Staphilococcus aureus</span> meticil&#237;n resistente&#59; PE&#58; progresi&#243;n de la enfermedad&#59; RC&#58; respuesta completa&#59; RG&#58; respuesta global&#59; RP&#58; respuesta parcial&#59; sc&#58; subcut&#225;nea&#59; tbc&#58; tuberculosis&#59; VEB&#58; virus Epstein Barr&#59; VHS&#58; virus herpes simple&#59; VVZ&#58; virus varicela z&#243;ster&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Series&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">N&#46;&#176; de pacientes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Pauta de alemtuzumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Duraci&#243;n del tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Respuesta cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Duraci&#243;n de la respuesta &#40;mediana&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Complicaciones graves&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Lundin J et al&#46;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">7</span></a> &#40;1998&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">50 LNH bajo grado&#40;8<span class="elsevierStyleHsp" style=""></span>MF&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30<span class="elsevierStyleHsp" style=""></span>mg v&#237;a iv 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6-12<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 20&#37;MF&#58; RG&#58; 50&#37;&#44; 2<span class="elsevierStyleHsp" style=""></span>RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Infecciones oportunistas &#40;7&#41;&#44; sepsis &#40;9&#41;&#44; neutropenia grado <span class="elsevierStyleSmallCaps">iv</span> &#40;14&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Lundin J et al&#46;<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">8</span></a> &#40;2003&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">22<span class="elsevierStyleHsp" style=""></span>MF&#47;SS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30 mg v&#237;a iv 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 55&#37;7<span class="elsevierStyleHsp" style=""></span>RC&#44; 5<span class="elsevierStyleHsp" style=""></span>RP&#44; 3<span class="elsevierStyleHsp" style=""></span>EE&#44; 7<span class="elsevierStyleHsp" style=""></span>PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Reactivaci&#243;n CMV &#40;4&#41;&#44; FOD &#40;3&#41;&#44; VHS generalizado &#40;1&#41;&#44; aspergilosis pulmonar &#40;1&#41;&#44; <span class="elsevierStyleItalic">Mycobacterium pneumoniae</span> &#40;1&#41;&#44; neutropenia febril &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Kennedy GA et al&#46;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">10</span></a> &#40;2003&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5<span class="elsevierStyleHsp" style=""></span>MF&#47;2<span class="elsevierStyleHsp" style=""></span>SS1<span class="elsevierStyleHsp" style=""></span>MF transformada a c&#233;lula grande&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30 mg v&#237;a iv 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3-13<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 38&#37;3<span class="elsevierStyleHsp" style=""></span>RP&#44; 2<span class="elsevierStyleHsp" style=""></span>EE&#44; 3<span class="elsevierStyleHsp" style=""></span>PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Menos de 3<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Pancitopenia grado <span class="elsevierStyleSmallCaps">iv</span> con sepsis &#40;2&#41;&#44; MRSA cut&#225;neo y VHS oral &#40;1&#41;&#44; bronquiolitis viral &#40;1&#41;&#44; VVZ cut&#225;neo &#40;1&#41;&#44; CMV &#40;1&#41;&#44; osteomielitis por <span class="elsevierStyleItalic">Pseudomona</span> e infecci&#243;n <span class="elsevierStyleItalic">Parvovirus</span> &#40;1&#41;&#44; sepsis por <span class="elsevierStyleItalic">Klebsiella</span> &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Ferrajoli et al&#46; <a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">11</span></a> &#40;2003&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6<span class="elsevierStyleHsp" style=""></span>LCCT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30 mg v&#237;a iv 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4-12<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2<span class="elsevierStyleHsp" style=""></span>RP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Capalbo S et al&#46;<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">12</span></a> &#40;2003&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1<span class="elsevierStyleHsp" style=""></span>MF&#47;2<span class="elsevierStyleHsp" style=""></span>SS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30 mg v&#237;a iv 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#44;6 y 12<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1<span class="elsevierStyleHsp" style=""></span>RC&#44; 1<span class="elsevierStyleHsp" style=""></span>RP&#44; 1 <span class="elsevierStyleItalic">&#233;xitus</span> &#40;IAM&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11<span class="elsevierStyleHsp" style=""></span>m3<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Lenihan DJ et al&#46;<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">13</span></a> &#40;2004&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5<span class="elsevierStyleHsp" style=""></span>SS y 3<span class="elsevierStyleHsp" style=""></span>MF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30 mg v&#237;a iv 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8&#44;5<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3<span class="elsevierStyleHsp" style=""></span>RP&#44; 2<span class="elsevierStyleHsp" style=""></span>EE&#44; 3<span class="elsevierStyleHsp" style=""></span>PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Eventos cardiovasculares &#40;5&#41;&#58; ICC&#47;arritmiasDos exitus por infecciones no especificadasUna neumon&#237;a <span class="elsevierStyleItalic">Legionella pneumoniae</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Zinzani et al&#46; <a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">14</span></a> &#40;2005&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4<span class="elsevierStyleHsp" style=""></span>MF6<span class="elsevierStyleHsp" style=""></span>LCT perif&#233;ricos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3<span class="elsevierStyleHsp" style=""></span>RP &#40;MF&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Reactivaci&#243;n CMV &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Bernengo et al&#46;<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">4</span></a> &#40;2007&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">14<span class="elsevierStyleHsp" style=""></span>SS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10-15<span class="elsevierStyleHsp" style=""></span>mg v&#237;a sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1<span class="elsevierStyleHsp" style=""></span>RC&#44; 11<span class="elsevierStyleHsp" style=""></span>RP&#44; 2<span class="elsevierStyleHsp" style=""></span>EE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Infecciones en pacientes tratados con 15<span class="elsevierStyleHsp" style=""></span>mg&#58;Sepsis estafiloc&#243;cica &#40;1&#41;Reactivaci&#243;n CMV subcl&#237;nica &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Alinari et al&#46;<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">15</span></a> &#40;2007&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5<span class="elsevierStyleHsp" style=""></span>SS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30<span class="elsevierStyleHsp" style=""></span>mg v&#237;a sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5-9<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 100&#37;5<span class="elsevierStyleHsp" style=""></span>RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Reactivaci&#243;n CMV asintom&#225;tica &#40;2&#41;&#44; reactivaci&#243;n VEB &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Querfeld et al&#46; <a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">16</span></a> &#40;2009&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">17<span class="elsevierStyleHsp" style=""></span>SS2<span class="elsevierStyleHsp" style=""></span>MF eritrod&#233;rmicas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30<span class="elsevierStyleHsp" style=""></span>mg v&#237;a iv y sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 84&#37;9<span class="elsevierStyleHsp" style=""></span>RC&#44; 7<span class="elsevierStyleHsp" style=""></span>RP&#44; 3<span class="elsevierStyleHsp" style=""></span>PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#201;xitus por pancitopenia grado <span class="elsevierStyleSmallCaps">iv</span> &#40;1&#41;Absceso cervical &#40;1&#41;&#44; sepsis por MRSA &#40;1&#41;&#44; herpes z&#243;ster &#40;1&#41;&#44; infecci&#243;n del cat&#233;ter central &#40;1&#41;&#44; neutropenia febril &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Clark et al&#46;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">6</span></a> &#40;2012&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">18<span class="elsevierStyleHsp" style=""></span>LCCT-L&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 89&#37;9<span class="elsevierStyleHsp" style=""></span>RC&#44; 7<span class="elsevierStyleHsp" style=""></span>RP&#44; 2<span class="elsevierStyleHsp" style=""></span>PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Reactivaci&#243;n CMV &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">De Masson et al&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">9</span></a> &#40;2014&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">23<span class="elsevierStyleHsp" style=""></span>SS&#47;16<span class="elsevierStyleHsp" style=""></span>MF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30<span class="elsevierStyleHsp" style=""></span>mg v&#237;a iv y sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 51&#37;&#40;70&#37; SS&#44; 25&#37; MF&#41;7<span class="elsevierStyleHsp" style=""></span>RC &#40;6<span class="elsevierStyleHsp" style=""></span>SS&#44; 1<span class="elsevierStyleHsp" style=""></span>MF&#41;13<span class="elsevierStyleHsp" style=""></span>RP &#40;10<span class="elsevierStyleHsp" style=""></span>SS&#44; 3<span class="elsevierStyleHsp" style=""></span>MF&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#44;4<span class="elsevierStyleHsp" style=""></span>m6ptes <span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>24<span class="elsevierStyleHsp" style=""></span>m&#40;5<span class="elsevierStyleHsp" style=""></span>SS&#44; 1<span class="elsevierStyleHsp" style=""></span>MF&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Viremia CMV &#40;10&#41;&#44; tbc &#40;2&#41;&#44; infecci&#243;n cut&#225;nea por <span class="elsevierStyleItalic">Mycobacterium chelonae</span> &#40;1&#41;&#44; infecci&#243;n bacteriana &#40;5&#41;&#44; toxoplasmosis &#40;1&#41;&#44; aspergilosis &#40;1&#41;&#44; neumon&#237;a &#40;7&#41;&#44; citopenias grado 3 &#40;10&#41;&#44; exitus &#40;2&#41;&#44; transformaci&#243;n a LCCT c&#233;lula grande &#40;5&#41;&#44; LCCB grande &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Watanabe et al&#46;<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">17</span></a> &#40;2014&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">17<span class="elsevierStyleHsp" style=""></span>SS&#47;6<span class="elsevierStyleHsp" style=""></span>MF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">SS&#58; 13 RC&#44; 4 RPMF&#58; 1 RC tras <span class="elsevierStyleItalic">electron beam</span>&#44; 5 PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Nuestra serie&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5<span class="elsevierStyleHsp" style=""></span>SS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 RC&#44;2 RP&#44; 1 PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Neumon&#237;a neumoc&#243;cica &#40;1&#41;Reactivaci&#243;n CMV asintom&#225;tica &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab884198.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Series publicadas de pacientes con SS&#47;MF tratados con alemtuzumab</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:18 [
            0 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primary cutaneous T-cell lymphoma &#40;mycosis fungoides and S&#233;zary syndrome&#41;&#58; Part I diagnosis&#58; Clinical and histopathologic features and new molecular and biologic markers"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46;I&#46; Jawed"
                            1 => "P&#46;L&#46; Myskowski"
                            2 => "S&#46; Horwitz"
                            3 => "A&#46; Moskowitz"
                            4 => "C&#46; Querfeld"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2014"
                        "volumen" => "70"
                        "paginaInicial" => "205e1"
                        "paginaFinal" => "2216e"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical end points and response criteria in mycosis fungoides and S&#233;zary syndrome&#58; A consensus statement of the International Society for Cutaneous Lymphomas&#44; the United States Cutaneous Lymphoma Consortium&#44; and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46;A&#46; Olsen"
                            1 => "S&#46; Whittaker"
                            2 => "Y&#46;H&#46; Kim"
                            3 => "M&#46; Duvic"
                            4 => "H&#46;M&#46; Prince"
                            5 => "S&#46;R&#46; Lessin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2010.32.0630"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2011"
                        "volumen" => "29"
                        "paginaInicial" => "2598"
                        "paginaFinal" => "2607"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21576639"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primary cutaneous T-cell lymphoma &#40;mycosis fungoides and S&#233;zary syndrome&#41;&#58; Part II prognosis&#44; management&#44; and future directions"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46;I&#46; Jawed"
                            1 => "P&#46;L&#46; Myskowski"
                            2 => "S&#46; Horwitz"
                            3 => "A&#46; Moskowitz"
                            4 => "C&#46; Querfeld"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2014"
                        "volumen" => "70"
                        "paginaInicial" => "223e1"
                        "paginaFinal" => "223e17"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome&#58; Clinical and immunologic findings in 14 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;G&#46; Bernengo"
                            1 => "P&#46; Quaglino"
                            2 => "A&#46; Comessatti"
                            3 => "M&#46; Ortoncelli"
                            4 => "M&#46; Novelli"
                            5 => "F&#46; Lisa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Haematologica"
                        "fecha" => "2007"
                        "volumen" => "92"
                        "paginaInicial" => "784"
                        "paginaFinal" => "794"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17550851"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Actualizaci&#243;n terap&#233;utica en linfomas cut&#225;neos"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R&#46;M&#46; Izu-Belloso"
                            1 => "J&#46;C&#46; Garcia-Ruiz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2012.01.011"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2012"
                        "volumen" => "103"
                        "paginaInicial" => "694"
                        "paginaFinal" => "707"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22575363"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;A&#46; Clark"
                            1 => "R&#46; Watanabe"
                            2 => "J&#46;E&#46; Teague"
                            3 => "C&#46; Schlapbach"
                            4 => "M&#46;C&#46; Tawa"
                            5 => "N&#46; Adams"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Sci Transl Med"
                        "fecha" => "2012"
                        "volumen" => "4"
                        "paginaInicial" => "117ra117"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin&#39;s lymphomas&#58; A phase II multicenter study European Study Group of CAMPATH-1H treatment in low-grade non-Hodgkin&#39;s lymphoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Lundin"
                            1 => "A&#46; Osterborg"
                            2 => "G&#46; Brittinger"
                            3 => "D&#46; Crowther"
                            4 => "H&#46; Dombret"
                            5 => "A&#46; Engert"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/jco.1998.16.10.3257"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "1998"
                        "volumen" => "16"
                        "paginaInicial" => "3257"
                        "paginaFinal" => "3263"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9779699"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Phase 2 study of alemtuzumab &#40;anti-CD52 monoclonal antibody&#41; in patients with advanced mycosis fungoides&#47;S&#233;zary syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Lundin"
                            1 => "H&#46; Hagberg"
                            2 => "R&#46; Repp"
                            3 => "E&#46; Cavallin-St&#229;hl"
                            4 => "S&#46; Fred&#233;n"
                            5 => "G&#46; Juliusson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2002-09-2802"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2003"
                        "volumen" => "101"
                        "paginaInicial" => "4267"
                        "paginaFinal" => "4272"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12543862"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; De Masson"
                            1 => "P&#46; Guitera"
                            2 => "P&#46; Brice"
                            3 => "I&#46; Moulonguet"
                            4 => "F&#46; Mouly"
                            5 => "J&#46;D&#46; Bouaziz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.12690"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2014"
                        "volumen" => "170"
                        "paginaInicial" => "720"
                        "paginaFinal" => "724"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24438061"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of patients with advanced mycosis fungoides and S&#233;zary syndrome with alemtuzumab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46;A&#46; Kennedy"
                            1 => "J&#46;F&#46; Seymour"
                            2 => "M&#46; Wolf"
                            3 => "H&#46; Januszewicz"
                            4 => "J&#46; Davison"
                            5 => "C&#46; McCormack"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Haematol"
                        "fecha" => "2003"
                        "volumen" => "71"
                        "paginaInicial" => "250"
                        "paginaFinal" => "256"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12950233"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Phase II study of alemtuzumab in chronic lymphoproliferative disorders"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Ferrajoli"
                            1 => "S&#46;M&#46; O&#8217;Brien"
                            2 => "J&#46;E&#46; Cortes"
                            3 => "F&#46;J&#46; Giles"
                            4 => "D&#46;A&#46; Thomas"
                            5 => "S&#46; Faderl"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cncr.11551"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer"
                        "fecha" => "2003"
                        "volumen" => "98"
                        "paginaInicial" => "773"
                        "paginaFinal" => "778"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12910522"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Mycosis fungoides&#47;S&#233;zary syndrome&#58; A report of three cases treated with Campath-1H as salvage treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Capalbo"
                            1 => "M&#46; Delia"
                            2 => "M&#46; Dargenio"
                            3 => "A&#46; Liso"
                            4 => "D&#46; Diomede"
                            5 => "L&#46; Garofalo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1385/MO:20:4:389"
                      "Revista" => array:6 [
                        "tituloSerie" => "Med Oncol"
                        "fecha" => "2003"
                        "volumen" => "20"
                        "paginaInicial" => "389"
                        "paginaFinal" => "396"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14716037"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiac toxicity of alemtuzumab in patients with mycosis fungoides&#47;S&#233;zary syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "D&#46;J&#46; Lenihan"
                            1 => "A&#46;J&#46; Alencar"
                            2 => "D&#46; Yang"
                            3 => "R&#46; Kurzrock"
                            4 => "M&#46;J&#46; Keating"
                            5 => "M&#46; Duvic"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2003-07-2345"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2004"
                        "volumen" => "104"
                        "paginaInicial" => "655"
                        "paginaFinal" => "658"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15073032"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "P&#46;L&#46; Zinzani"
                            1 => "L&#46; Alinari"
                            2 => "M&#46; Tani"
                            3 => "M&#46; Fina"
                            4 => "S&#46; Pileri"
                            5 => "M&#46; Baccarani"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Haematologica"
                        "fecha" => "2005"
                        "volumen" => "90"
                        "paginaInicial" => "702"
                        "paginaFinal" => "703"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15921394"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Subcutaneous alemtuzumab for S&#233;zary syndrome in the very elderly"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "L&#46; Alinari"
                            1 => "L&#46; Geskin"
                            2 => "T&#46; Grady"
                            3 => "R&#46;A&#46; Baiocchi"
                            4 => "M&#46;A&#46; Bechtel"
                            5 => "P&#46; Porcu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.leukres.2007.11.009"
                      "Revista" => array:6 [
                        "tituloSerie" => "Leuk Res"
                        "fecha" => "2008"
                        "volumen" => "32"
                        "paginaInicial" => "1299"
                        "paginaFinal" => "1303"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18096224"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma&#58; A single institution experience from the Robert H Lurie Comprehensive Cancer Center"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Querfeld"
                            1 => "N&#46; Mehta"
                            2 => "S&#46;T&#46; Rosen"
                            3 => "J&#46; Guitart"
                            4 => "A&#46; Rademaker"
                            5 => "P&#46; Gerami"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3109/10428190903216770"
                      "Revista" => array:6 [
                        "tituloSerie" => "Leuk Lymphoma"
                        "fecha" => "2009"
                        "volumen" => "50"
                        "paginaInicial" => "1969"
                        "paginaFinal" => "1976"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19860617"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma&#58; Diffuse erythema as a positive predictor of complete remission"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "R&#46; Watanabe"
                            1 => "J&#46;E&#46; Teague"
                            2 => "D&#46;C&#46; Fisher"
                            3 => "T&#46;S&#46; Kupper"
                            4 => "R&#46;A&#46; Clark"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2013.10099"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol"
                        "fecha" => "2014"
                        "volumen" => "150"
                        "paginaInicial" => "776"
                        "paginaFinal" => "779"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24760312"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous hemophagocytosis after alemtuzumab injection in a patient with S&#233;zary syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46;I&#46; Jawed"
                            1 => "K&#46; Busam"
                            2 => "X&#46; Wang"
                            3 => "S&#46; Horwitz"
                            4 => "C&#46; Querfeld"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2013.10615"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol"
                        "fecha" => "2014"
                        "volumen" => "150"
                        "paginaInicial" => "1021"
                        "paginaFinal" => "1023"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25029560"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000010600000007/v1_201509041239/S0001731015001477/v1_201509041239/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "24962"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "e-Casos cl&#237;nicos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000010600000007/v1_201509041239/S0001731015001477/v1_201509041239/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731015001477?idApp=UINPBA000044"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

e-Casos clínicos
Tratamiento del síndrome de Sézary con alemtuzumab: serie de 5 casos y revisión de la literatura
Treatment of Sézary Syndrome With Alemtuzumab: A Series of 5 Cases and a Review of the Literature
E. del Alcázar-Viladomiua,
Autor para correspondencia
elenadelalcazarviladomiu@gmail.com

Autor para correspondencia.
, A. Tuneu-Vallsa, A. López-Pestañaa, M.J. Vidal-Manceñidob
a Servicio de Dermatología, Hospital Universitario Donostia, San Sebastián, España
b Servicio de Hematología, Hospital Universitario Donostia, San Sebastián, España
Leído
8357
Veces
se ha leído el artículo
2340
Total PDF
6017
Total HTML
Compartir estadísticas
 array:24 [
  "pii" => "S0001731015001477"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2015.02.008"
  "estado" => "S300"
  "fechaPublicacion" => "2015-09-01"
  "aid" => "1153"
  "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; y AEDV"
  "copyrightAnyo" => "2014"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "crp"
  "cita" => "Actas Dermosifiliogr. 2015;106:e33-9"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 863
    "formatos" => array:3 [
      "EPUB" => 2
      "HTML" => 497
      "PDF" => 364
    ]
  ]
  "Traduccion" => array:1 [
    "en" => array:18 [
      "pii" => "S1578219015001705"
      "issn" => "15782190"
      "doi" => "10.1016/j.adengl.2015.06.005"
      "estado" => "S300"
      "fechaPublicacion" => "2015-09-01"
      "aid" => "1153"
      "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
      "documento" => "simple-article"
      "subdocumento" => "crp"
      "cita" => "Actas Dermosifiliogr. 2015;106:e33-9"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 956
        "formatos" => array:3 [
          "EPUB" => 54
          "HTML" => 578
          "PDF" => 324
        ]
      ]
      "en" => array:13 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">e-Case Report</span>"
        "titulo" => "Treatment of S&#233;zary Syndrome With Alemtuzumab&#58; A Series of 5 Cases and a Review of the Literature"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => array:2 [
          0 => "en"
          1 => "es"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "e33"
            "paginaFinal" => "e39"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "es" => array:1 [
            "titulo" => "Tratamiento del s&#237;ndrome de S&#233;zary con alemtuzumab&#58; serie de 5 casos y revisi&#243;n de la literatura"
          ]
        ]
        "contieneResumen" => array:2 [
          "en" => true
          "es" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:7 [
            "identificador" => "fig0005"
            "etiqueta" => "Figure 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 538
                "Ancho" => 1500
                "Tamanyo" => 162726
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">A&#44; Erythematous lesions on the abdomen of a patient with SS before starting treatment with alemtuzumab &#40;case<span class="elsevierStyleHsp" style=""></span>3&#41;&#46; B&#44; In the same patient&#44; resolution of the erythema 4 weeks after starting treatment with alemtuzumab&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "E&#46; del Alc&#225;zar-Viladomiu, A&#46; Tuneu-Valls, A&#46; L&#243;pez-Pesta&#241;a, M&#46;J&#46; Vidal-Mance&#241;ido"
            "autores" => array:4 [
              0 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "del Alc&#225;zar-Viladomiu"
              ]
              1 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "Tuneu-Valls"
              ]
              2 => array:2 [
                "nombre" => "A&#46;"
                "apellidos" => "L&#243;pez-Pesta&#241;a"
              ]
              3 => array:2 [
                "nombre" => "M&#46;J&#46;"
                "apellidos" => "Vidal-Mance&#241;ido"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "es" => array:9 [
          "pii" => "S0001731015001477"
          "doi" => "10.1016/j.ad.2015.02.008"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "es"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731015001477?idApp=UINPBA000044"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219015001705?idApp=UINPBA000044"
      "url" => "/15782190/0000010600000007/v1_201508271313/S1578219015001705/v1_201508271313/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:19 [
    "pii" => "S0001731015001258"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2015.01.013"
    "estado" => "S300"
    "fechaPublicacion" => "2015-09-01"
    "aid" => "1141"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; y AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "cor"
    "cita" => "Actas Dermosifiliogr. 2015;106:579-80"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 695
      "formatos" => array:3 [
        "EPUB" => 3
        "HTML" => 377
        "PDF" => 315
      ]
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Casos para el diagn&#243;stico</span>"
      "titulo" => "N&#243;dulos frontales asociados a adenopat&#237;as generalizadas"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "579"
          "paginaFinal" => "580"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Nodules on the Forehead Associated With Generalized Lymphadenopathy"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:6 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 921
              "Ancho" => 950
              "Tamanyo" => 184550
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A&#46; Lobato-Berezo, F&#46; Burgos-L&#225;zaro, M&#46;&#193;&#46; Gallego-Vald&#233;s"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Lobato-Berezo"
            ]
            1 => array:2 [
              "nombre" => "F&#46;"
              "apellidos" => "Burgos-L&#225;zaro"
            ]
            2 => array:2 [
              "nombre" => "M&#46;&#193;&#46;"
              "apellidos" => "Gallego-Vald&#233;s"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1578219015001729"
        "doi" => "10.1016/j.adengl.2015.06.007"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219015001729?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731015001258?idApp=UINPBA000044"
    "url" => "/00017310/0000010600000007/v1_201509041239/S0001731015001258/v1_201509041239/es/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S0001731015001416"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2015.02.003"
    "estado" => "S300"
    "fechaPublicacion" => "2015-09-01"
    "aid" => "1147"
    "copyright" => "Elsevier Espa&#241;a&#44; S&#46;L&#46;U&#46; and AEDV"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "fla"
    "cita" => "Actas Dermosifiliogr. 2015;106:569-77"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 995
      "formatos" => array:3 [
        "EPUB" => 2
        "HTML" => 602
        "PDF" => 391
      ]
    ]
    "es" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original</span>"
      "titulo" => "Modificaci&#243;n de la dosis de terapias biol&#243;gicas en psoriasis moderada-grave&#58; an&#225;lisis descriptivo en condiciones de pr&#225;ctica cl&#237;nica"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "569"
          "paginaFinal" => "577"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis&#58; A Descriptive Analysis in a Clinical Practice Setting"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1492
              "Ancho" => 2655
              "Tamanyo" => 172383
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Algoritmo del tratamiento seguido en el estudio&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "O&#46; Baniandr&#233;s, V&#46;J&#46; Rodr&#237;guez-Soria, R&#46;M&#46; Romero-Jim&#233;nez, R&#46; Su&#225;rez"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "O&#46;"
              "apellidos" => "Baniandr&#233;s"
            ]
            1 => array:2 [
              "nombre" => "V&#46;J&#46;"
              "apellidos" => "Rodr&#237;guez-Soria"
            ]
            2 => array:2 [
              "nombre" => "R&#46;M&#46;"
              "apellidos" => "Romero-Jim&#233;nez"
            ]
            3 => array:2 [
              "nombre" => "R&#46;"
              "apellidos" => "Su&#225;rez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S1578219015001699"
        "doi" => "10.1016/j.adengl.2015.06.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219015001699?idApp=UINPBA000044"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731015001416?idApp=UINPBA000044"
    "url" => "/00017310/0000010600000007/v1_201509041239/S0001731015001416/v1_201509041239/es/main.assets"
  ]
  "es" => array:17 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">e-Casos cl&#237;nicos</span>"
    "titulo" => "Tratamiento del s&#237;ndrome de S&#233;zary con alemtuzumab&#58; serie de 5 casos y revisi&#243;n de la literatura"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "e33"
        "paginaFinal" => "e39"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "E&#46; del Alc&#225;zar-Viladomiu, A&#46; Tuneu-Valls, A&#46; L&#243;pez-Pesta&#241;a, M&#46;J&#46; Vidal-Mance&#241;ido"
        "autores" => array:4 [
          0 => array:4 [
            "nombre" => "E&#46;"
            "apellidos" => "del Alc&#225;zar-Viladomiu"
            "email" => array:1 [
              0 => "elenadelalcazarviladomiu&#64;gmail&#46;com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "Tuneu-Valls"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "A&#46;"
            "apellidos" => "L&#243;pez-Pesta&#241;a"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "M&#46;J&#46;"
            "apellidos" => "Vidal-Mance&#241;ido"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario Donostia&#44; San Sebasti&#225;n&#44; Espa&#241;a"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Hematolog&#237;a&#44; Hospital Universitario Donostia&#44; San Sebasti&#225;n&#44; Espa&#241;a"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspondencia&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Treatment of S&#233;zary Syndrome With Alemtuzumab&#58; A Series of 5 Cases and a Review of the Literature"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 538
            "Ancho" => 1500
            "Tamanyo" => 145000
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">A&#46; Lesiones eritematosas en el abdomen de una paciente con SS antes de iniciar el tratamiento con alemtuzumab &#40;caso 3&#41;&#46; B&#46; Desaparici&#243;n del eritema a las 4 semanas de iniciar el tratamiento con alemtuzumab &#40;caso 3&#41;&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introducci&#243;n</span><p id="par0005" class="elsevierStylePara elsevierViewall">El s&#237;ndrome de S&#233;zary &#40;SS&#41; es una entidad infrecuente que representa aproximadamente el 3&#37; de todos los linfomas cut&#225;neos de c&#233;lulas T&#46; Se considera una variante agresiva que se caracteriza por la presencia de eritrodermia&#44; linfocitos T at&#237;picos circulantes &#40;c&#233;lulas de S&#233;zary&#41; con o sin adenopat&#237;as<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">1</span></a>&#46; Se clasifica como un T4&#44; N0-3&#44; M0-1&#44; B2 seg&#250;n la <span class="elsevierStyleItalic">International Society for Cutaneous Lymphomas</span> &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">tabla 1</a>&#41;<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">1&#8211;3</span></a>&#46; El prurito es el s&#237;ntoma principal y puede llegar a tener un gran impacto en la calidad de vida&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0010" class="elsevierStylePara elsevierViewall">El pron&#243;stico es pobre&#44; con una supervivencia del 24&#37; a los 5 a&#241;os&#44; con pocas respuestas y remisiones duraderas tras los tratamientos<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">4</span></a>&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Para su tratamiento son necesarias terapias sist&#233;micas&#44; ya que las dirigidas exclusivamente a la piel son insuficientes&#46; La elecci&#243;n viene determinada por la extensi&#243;n de la enfermedad&#44; el impacto en la calidad de vida&#44; la edad y las comorbilidades del paciente&#46; Aunque existen diferentes tipos de tratamiento para el SS &#40;<a class="elsevierStyleCrossRef" href="#tbl0010">tabla 2</a>&#41;<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">3</span></a>&#44; hay pocos estudios sobre su eficacia&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">En los &#250;ltimos a&#241;os han aparecido nuevas terap&#233;uticas&#44; entre las que encontramos las terapias biol&#243;gicas&#46; El alemtuzumab es un anticuerpo monoclonal humanizado dirigido contra la glucoprote&#237;na CD52 que se expresa en la superficie de los linfocitos T y B&#44; c&#233;lulas <span class="elsevierStyleItalic">natural killer</span>&#44; monocitos y macr&#243;fagos&#44; consiguiendo su depleci&#243;n en sangre perif&#233;rica<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">3&#44;5</span></a>&#46; Se cree que act&#250;a por lisis celular directa mediada por neutr&#243;filos&#44; complemento y citotoxicidad dependiente de anticuerpos y apoptosis<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">3&#8211;6</span></a>&#46; En el a&#241;o 2001 se aprob&#243; su uso para el tratamiento de la leucemia linf&#225;tica cr&#243;nica B&#44; aunque algunos autores lo han utilizado en casos refractarios de SS y MF en estadio avanzado&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Casos cl&#237;nicos</span><p id="par0025" class="elsevierStylePara elsevierViewall">Presentamos 5 pacientes &#40;3 mujeres y 2 hombres&#41; diagnosticados de SS estadio IVA<span class="elsevierStyleInf">1</span> &#40;T4&#44; N0&#44; M0&#44; B2&#41; tratados con alemtuzumab desde el a&#241;o 2008 hasta el 2012&#46; Cuatro hab&#237;an realizado tratamientos previos &#40;fototerapia&#44; prednisona&#44; metotrexato&#44; gemcitabina y bexaroteno&#41;&#46;</p><p id="par0030" class="elsevierStylePara elsevierViewall">Respecto al tratamiento con alemtuzumab hemos recogido las siguientes variables &#40;<a class="elsevierStyleCrossRef" href="#tbl0015">tabla 3</a>&#41;&#58; 1&#41; duraci&#243;n&#59; 2&#41; tipo de respuesta&#59; 3&#41; tiempo transcurrido hasta el inicio de la respuesta&#59; 4&#41; duraci&#243;n de la misma tras la suspensi&#243;n del tratamiento&#59; y 5&#41; las c&#233;lulas de S&#233;zary en sangre perif&#233;rica&#46; Adem&#225;s&#44; hemos analizado la evoluci&#243;n&#44; el tiempo de seguimiento y las complicaciones asociadas al alemtuzumab&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">Hemos clasificado el tipo de respuesta de la siguiente manera&#58; completa &#40;RC&#41;&#44; parcial &#40;RP&#41; o progresi&#243;n de la enfermedad &#40;PE&#41;&#44; bas&#225;ndonos en el trabajo de Olsen et al&#46;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">2</span></a> &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>&#41;&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0040" class="elsevierStylePara elsevierViewall">La pauta utilizada fue la administraci&#243;n subcut&#225;nea de una primera dosis inicial de 3<span class="elsevierStyleHsp" style=""></span>mg y posteriormente 10<span class="elsevierStyleHsp" style=""></span>mg 3 veces por semana&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">Los 5 pacientes recibieron profilaxis oral para <span class="elsevierStyleItalic">Pneumocystis jiroveci</span> con sulfametoxazol-trimetroprim&#44; aciclovir para herpes y fluconazol para <span class="elsevierStyleItalic">Candida</span>&#46; Para la profilaxis de citomegalovirus &#40;CMV&#41; se realiz&#243; carga viral semanal&#44; utilizando tratamiento anticipatorio con valganciclovir oral en los casos de reactivaci&#243;n&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">En cuanto a los resultados se obtuvo respuesta en 4 de 5 pacientes &#40;tasa de respuesta global del 80&#37;&#41;&#58; 2 RP &#40;40&#37;&#41; y 2 RC &#40;40&#37;&#41;&#46; La mediana de duraci&#243;n del tratamiento fue de 8 semanas &#40;4-13&#41; y la mediana de duraci&#243;n de la respuesta tras suspender el tratamiento de 13 meses &#40;5-66&#41;&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">Como complicaciones un paciente present&#243; una neumon&#237;a neumoc&#243;cica&#44; 3 un s&#237;ndrome de liberaci&#243;n de citocinas y tuvimos 2 casos de reactivaciones subcl&#237;nicas de CMV&#46; No tuvimos ning&#250;n caso de complicaci&#243;n hematol&#243;gica&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">La mediana de seguimiento fue de 27 meses &#40;23-67&#41; tras el inicio del tratamiento&#46; Un paciente falleci&#243; a los 24 meses por una transformaci&#243;n a un linfoma no Hodgkin de alto grado&#46; Actualmente&#44; 3 pacientes est&#225;n en progresi&#243;n y una sigue en remisi&#243;n completa tras 67 meses de finalizar el tratamiento&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Discusi&#243;n</span><p id="par0065" class="elsevierStylePara elsevierViewall">El alemtuzumab se ha utilizado tanto en casos refractarios de MF en estadio avanzado como de SS&#46; La primera descripci&#243;n es de 1998 en 8 pacientes con MF<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">7</span></a>&#46; En 2003 se demostr&#243; su utilidad en un estudio en fase <span class="elsevierStyleSmallCaps">ii</span> en 22 pacientes con MF&#47;SS<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">8</span></a>&#46; Desde entonces se han publicado algunas series cortas y casos aislados&#46; En la literatura revisada hemos encontrado un total de 13 series<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">4&#44;6&#8211;17</span></a> y 6 casos aislados de MF y SS recogi&#233;ndose las primeras en la <a class="elsevierStyleCrossRef" href="#tbl0020">tabla 4</a>&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0070" class="elsevierStylePara elsevierViewall">Respecto a la respuesta tras el tratamiento&#44; en los 2 trabajos m&#225;s amplios&#44; de 22 y 39 pacientes&#44; la tasa de respuesta global fue del 55&#37; y 51&#37; respectivamente<a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">8&#44;9</span></a>&#46; La duraci&#243;n mediana de la respuesta fue de 12 meses&#44; aunque es variable seg&#250;n las distintas series<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">4&#44;6&#8211;17</span></a>&#46; En la serie de 39 casos se observ&#243; que el alemtuzumab puede inducir remisiones duraderas &#40;m&#225;s de 2 a&#241;os&#41; en el SS &#40;5 pacientes&#41;&#44; no as&#237; en los casos de MF &#40;un caso&#41;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">9</span></a>&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">La pauta de tratamiento ha variado con los a&#241;os&#46; La dosis utilizada en los primeros trabajos era v&#237;a intravenosa&#58; una primera dosis inicial de 3<span class="elsevierStyleHsp" style=""></span>mg&#44; luego 10<span class="elsevierStyleHsp" style=""></span>mg y finalmente 30<span class="elsevierStyleHsp" style=""></span>mg&#44; manteniendo esta &#250;ltima dosis 3 veces por semana<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">7&#44;8&#44;10&#8211;13</span></a>&#46; Posteriormente&#44; se observ&#243; que el alemtuzumab v&#237;a subcut&#225;nea a dosis bajas podr&#237;a ser igual de efectivo<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">4&#44;14</span></a>&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">Las infecciones y la toxicidad hematol&#243;gica son complicaciones ligadas al tratamiento&#46; La pauta de 10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a subcut&#225;nea ha demostrado una menor incidencia de estos efectos adversos<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">4&#44;14&#44;15</span></a>&#46; La infecci&#243;n oportunista m&#225;s frecuente es la reactivaci&#243;n del CMV&#44; aunque tambi&#233;n se han descrito otros tipos de infecciones<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">4</span></a>&#46; En cuanto a la toxicidad hematol&#243;gica&#44; la mielosupresi&#243;n es la m&#225;s com&#250;n<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">4</span></a>&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">El s&#237;ndrome de liberaci&#243;n de citocinas es la complicaci&#243;n m&#225;s frecuente durante la terapia<a class="elsevierStyleCrossRefs" href="#bib0125"><span class="elsevierStyleSup">7&#44;8&#44;10&#44;11</span></a>&#46; Para disminuir su aparici&#243;n se realiza una escalada progresiva de la dosis&#46; <span class="elsevierStyleItalic">Lenihan</span> et al&#46; publicaron 4 casos de toxicidad card&#237;aca durante el tratamiento en pacientes previamente sanos<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">13</span></a>&#46; Dado que no se observ&#243; en ning&#250;n otro estudio&#44; se ha puesto en entredicho esta relaci&#243;n causal&#46; Recientemente se ha descrito un caso de hematofagocitosis cut&#225;nea localizada en el sitio de inyecci&#243;n del alemtuzumab en una paciente sin reactivaci&#243;n viral del Epstein-Barr<a class="elsevierStyleCrossRef" href="#bib0180"><span class="elsevierStyleSup">18</span></a>&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">En la literatura revisada el alemtuzumab se ha utilizado indistintamente tanto para la MF como para el SS&#46; De hecho&#44; la mayor&#237;a de los trabajos agrupan el SS con la MF en estadio avanzado&#46; Actualmente se considera que la MF eritrod&#233;rmica es una progresi&#243;n de la MF con ausencia o poca afectaci&#243;n hematol&#243;gica&#44; a diferencia de lo que acontece en el SS&#44; que aparece <span class="elsevierStyleItalic">de novo</span> y tiene una importante afectaci&#243;n sangu&#237;nea<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">1</span></a>&#46; En 2012 Clark et al&#46; publicaron que el alemtuzumab podr&#237;a ser eficaz solo cuando existiera afectaci&#243;n hematol&#243;gica &#40;en el SS y en casos de MF eritrod&#233;rmica con afectaci&#243;n sangu&#237;nea&#41;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">6</span></a>&#46; Estos autores postulan que ambas entidades provienen de distintos tipos de c&#233;lulas T memoria&#58; los linfocitos malignos en pacientes con SS presentar&#237;an un fenotipo de c&#233;lulas memoria central CCR7&#43;&#47;L-selectina&#43; &#40;c&#233;lulas migratorias que se encuentran circulando en la sangre&#44; en la piel y en los ganglios linf&#225;ticos&#41;&#44; mientras que los linfocitos malignos de la MF derivar&#237;an de c&#233;lulas no migratorias residentes en la piel que no circulan por la sangre&#46; El alemtuzumab deplecionar&#237;a todos los linfocitos T en la sangre&#44; pero la poblaci&#243;n de c&#233;lulas residentes en la piel escapar&#237;a del efecto del anticuerpo&#44; permaneciendo despu&#233;s del tratamiento&#46; Adem&#225;s&#44; el alemtuzumab requiere la presencia de neutr&#243;filos y c&#233;lulas <span class="elsevierStyleItalic">natural killer</span> &#40;ambas presentes en sangre y no en piel&#41; para la depleci&#243;n de linfocitos&#44; por lo que solo eliminar&#237;a las c&#233;lulas en sangre perif&#233;rica&#46; De esta forma&#44; los pacientes con SS ser&#237;an los principales candidatos para este tratamiento&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">Lamentablemente&#44; en agosto de 2012 se anul&#243; su uso para la leucemia linf&#225;tica cr&#243;nica B y otras enfermedades hematol&#243;gicas&#44; y actualmente solo est&#225; disponible para la esclerosis m&#250;ltiple&#46; Para el tratamiento en pacientes con SS solo se puede conseguir mediante acceso individualizado con protocolo&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Conclusiones</span><p id="par0100" class="elsevierStylePara elsevierViewall">Presentamos 5 casos de SS tratados con alemtuzumab con una tasa de respuesta del 80&#37;&#46; La pauta de 10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a subcut&#225;nea fue bien tolerada y la mediana de duraci&#243;n de la respuesta fue de 13 meses&#46; El alemtuzumab puede ser un f&#225;rmaco &#250;til en casos de SS refractarios a otros tratamientos&#44; con una r&#225;pida respuesta cl&#237;nica y mejor&#237;a de la calidad de vida con disminuci&#243;n o desaparici&#243;n del prurito&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Conflicto de intereses</span><p id="par0105" class="elsevierStylePara elsevierViewall">Los autores declaran no tener ning&#250;n conflicto de intereses&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Responsabilidades &#233;ticas</span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Protecci&#243;n de personas y animales</span><p id="par0110" class="elsevierStylePara elsevierViewall">Los autores declaran que para esta investigaci&#243;n no se han realizado experimentos en seres humanos ni en animales&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Confidencialidad de los datos</span><p id="par0115" class="elsevierStylePara elsevierViewall">Los autores declaran que en este art&#237;culo no aparecen datos de pacientes&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Derecho a la privacidad y consentimiento informado</span><p id="par0120" class="elsevierStylePara elsevierViewall">Los autores declaran que en este art&#237;culo no aparecen datos de pacientes&#46;</p></span></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:11 [
        0 => array:3 [
          "identificador" => "xres547424"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec565303"
          "titulo" => "Palabras clave"
        ]
        2 => array:3 [
          "identificador" => "xres547425"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec565302"
          "titulo" => "Keywords"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introducci&#243;n"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Casos cl&#237;nicos"
        ]
        6 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Discusi&#243;n"
        ]
        7 => array:2 [
          "identificador" => "sec0020"
          "titulo" => "Conclusiones"
        ]
        8 => array:2 [
          "identificador" => "sec0025"
          "titulo" => "Conflicto de intereses"
        ]
        9 => array:3 [
          "identificador" => "sec0030"
          "titulo" => "Responsabilidades &#233;ticas"
          "secciones" => array:3 [
            0 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Protecci&#243;n de personas y animales"
            ]
            1 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "Confidencialidad de los datos"
            ]
            2 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Derecho a la privacidad y consentimiento informado"
            ]
          ]
        ]
        10 => array:1 [
          "titulo" => "Bibliograf&#237;a"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec565303"
          "palabras" => array:3 [
            0 => "S&#237;ndrome de S&#233;zary"
            1 => "Alemtuzumab"
            2 => "Tratamiento"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec565302"
          "palabras" => array:3 [
            0 => "S&#233;zary syndrome"
            1 => "Alemtuzumab"
            2 => "Treatment"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">El alemtuzumab es un anticuerpo monoclonal que se ha utilizado como terap&#233;utica en casos refractarios de s&#237;ndrome de S&#233;zary &#40;SS&#41; y micosis fungoide en estadio avanzado&#46;</p><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Presentamos 5 pacientes diagnosticados de SS tratados con alemtuzumab entre los a&#241;os 2008 y 2012&#44; con una tasa de respuesta global del 80&#37; &#40;40&#37; respuestas parciales y 40&#37; respuestas completas&#41;&#46; La pauta de 10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a subcut&#225;nea fue bien tolerada y con una toxicidad aceptable&#46; En nuestra casu&#237;stica la mediana de duraci&#243;n de la respuesta fue de 13 meses&#44; sin embargo uno de los pacientes contin&#250;a en remisi&#243;n completa tras 67 meses&#44; hecho destacable dada la baja supervivencia del SS&#46;</p><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Como conclusi&#243;n&#44; creemos que el alemtuzumab es un f&#225;rmaco que podr&#237;a ser &#250;til en casos de SS refractarios a otros tratamientos&#46; Dado que no existen tratamientos curativos en el SS&#44; ser&#237;a una alternativa terap&#233;utica a tener en cuenta&#46;</p></span>"
      ]
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Alemtuzumab is a monoclonal antibody that has been used to treat refractory cases of S&#233;zary syndrome &#40;SS&#41; and advanced mycosis fungoides&#46;</p><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">We present 5 patients with SS who were treated with alemtuzumab between 2008 and 2012&#44; with an overall response rate of 80&#37; &#40;40&#37; partial response and 40&#37; complete response&#41;&#46; A regimen of 10<span class="elsevierStyleHsp" style=""></span>mg administered subcutaneously was well tolerated with acceptable toxicity&#46; The median duration of response was 13 months&#46; However&#44; one patient remains in complete remission after 67 months&#44; a remarkable outcome given the low survival rate associated with SS&#46;</p><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">In conclusion&#44; we believe that alemtuzumab may be useful in cases of SS refractory to other treatments&#46; As there are no curative treatments for SS&#44; alemtuzumab should be considered as a therapeutic option&#46;</p></span>"
      ]
    ]
    "multimedia" => array:5 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 538
            "Ancho" => 1500
            "Tamanyo" => 145000
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">A&#46; Lesiones eritematosas en el abdomen de una paciente con SS antes de iniciar el tratamiento con alemtuzumab &#40;caso 3&#41;&#46; B&#46; Desaparici&#243;n del eritema a las 4 semanas de iniciar el tratamiento con alemtuzumab &#40;caso 3&#41;&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabla 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">EORTC&#58; <span class="elsevierStyleItalic">European Organisation for Research and Treatment of Cancer</span>&#59; ISCL <span class="elsevierStyleItalic">International Society for Cutaneous Lymphomas</span>&#59; LN&#58; <span class="elsevierStyleItalic">lymph node</span>&#59; NCI&#58; <span class="elsevierStyleItalic">National Cancer Institute</span>&#59; TCR&#58; receptor de linfocito T&#46;</p><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Fuente&#58; Olsen et al&#46;<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">2</span></a>&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Piel &#40;T&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>T1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">M&#225;culas limitadas&#44; p&#225;pulas y&#47;o placas cubriendo &#60;<span class="elsevierStyleHsp" style=""></span>10&#37; de la superficie cut&#225;nea&#46; T<span class="elsevierStyleInf">1a</span> &#40;solo m&#225;culas&#41; y T<span class="elsevierStyleInf">1b</span> &#40;m&#225;culas y placas&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>T2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">M&#225;culas&#44; p&#225;pulas y&#47;o placas cubriendo &#8805;<span class="elsevierStyleHsp" style=""></span>10&#37; de la superficie cut&#225;nea&#46; T<span class="elsevierStyleInf">2a</span> &#40;solo m&#225;culas&#41; y T<span class="elsevierStyleInf">2b</span> &#40;m&#225;culas y placas&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>T3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Uno o m&#225;s tumores &#40;&#62;<span class="elsevierStyleHsp" style=""></span>1<span class="elsevierStyleHsp" style=""></span>cm de di&#225;metro&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>T4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Confluencia de eritema<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>80&#37; de la superficie cut&#225;nea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Ganglios&#40;N&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>N0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No ganglios linf&#225;ticos perif&#233;ricos anormales&#44; la biopsia no es necesaria&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>N1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ganglios perif&#233;ricos cl&#237;nicamente anormales&#44; histol&#243;gicamente Dutch grado 1 o NCI LN<span class="elsevierStyleInf">0-2</span>&#46; N<span class="elsevierStyleInf">1a</span> clonalidad negativa y N<span class="elsevierStyleInf">1b</span> clonalidad positiva&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>N2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ganglios perif&#233;ricos cl&#237;nicamente anormales&#44; histol&#243;gicamente Dutch grado 2 o NCI LN<span class="elsevierStyleInf">3</span>&#46; N<span class="elsevierStyleInf">2a</span> clonalidad negativa y N<span class="elsevierStyleInf">2b</span> clonalidad positiva&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>N3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ganglios perif&#233;ricos cl&#237;nicamente anormales&#44; histol&#243;gicamente Dutch grado 3-4 o NCI LN<span class="elsevierStyleInf">4</span> clonalidad positiva o negativa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Nx&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ganglios perif&#233;ricos cl&#237;nicamente anormales sin confirmaci&#243;n histol&#243;gica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Visceral &#40;M&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>M0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No existencia de afectaci&#243;n visceral&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>M1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Afectaci&#243;n visceral &#40;debe tener confirmaci&#243;n histol&#243;gica y debe especificarse el &#243;rgano&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Hematol&#243;gica &#40;B&#41;</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>B0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Ausencia de afectaci&#243;n hematol&#243;gica significativa &#40;&#8804;<span class="elsevierStyleHsp" style=""></span>5&#37; de linfocitos at&#237;picos&#47;c&#233;lulas de S&#233;zary&#41;&#46; B<span class="elsevierStyleInf">0a</span> clonalidad negativa y B<span class="elsevierStyleInf">0b</span> clonalidad positiva&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>B1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Baja afectaci&#243;n hematol&#243;gica &#40;&#62;<span class="elsevierStyleHsp" style=""></span>5&#37; de linfocitos at&#237;picos&#47;c&#233;lulas de S&#233;zary&#41;&#46; B<span class="elsevierStyleInf">1a</span> clonalidad negativa y B<span class="elsevierStyleInf">1b</span> clonalidad positiva&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>B2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Alta afectaci&#243;n hematol&#243;gica definida como uno de los siguientes&#58; &#8805;<span class="elsevierStyleHsp" style=""></span>1&#46;000 c&#233;lulas de S&#233;zary&#47;&#956;l con TCR positivo&#59; CD4&#47;CD8<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10 con TCR positivo&#59; o c&#233;lulas CD4&#43; CD7&#8211;<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>40&#37; o CD4&#43; CD26&#8211; &#8805;<span class="elsevierStyleHsp" style=""></span>30&#37; con TCR positivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab884196.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Clasificaci&#243;n de la micosis fungoide&#47;s&#237;ndrome de S&#233;zary propuesta por la ISCL y la EORTC</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabla 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">IFN&#58; interfer&#243;n&#59; TPMO&#58; transplante de progenitores de m&#233;dula &#243;sea&#46;</p><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Fuente&#58; modificada de Jawed et al&#46;<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">3</span></a>&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Tipo de terapia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Inmunomoduladores</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Interfer&#243;n &#40;IFN alfa e IFN gamma&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Retinoide &#40;bexaroteno&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Denileukin diftitox&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Fotof&#233;resis extracorp&#243;rea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Terapias biol&#243;gicas</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Alemtuzumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Radioterapia</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Irradiaci&#243;n corporal total con electrones <span class="elsevierStyleItalic">&#40;electron beam&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">Tratamientos combinados</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">IFN alfa<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>fototerapia o retinoide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Retinoide<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>fototerapia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Fotof&#233;resis extracorp&#243;rea<span class="elsevierStyleHsp" style=""></span>&#43;<span class="elsevierStyleHsp" style=""></span>IFN alfa o retinoide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry  " colspan="2" align="left" valign="top"><span class="elsevierStyleItalic">Quimioterapia sist&#233;mica</span></td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Monoterapia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Metotrexato&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Doxorrubicina pegilada&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Poliquimioterapia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">An&#225;logos de las purinas&#47;pirimidinas &#40;fludarabina&#44; 2-clorodeoxiadenosina&#44; deoxicoformicina&#44; gemcitabina&#44; forodesina&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Agentes alquilantes &#40;clorambucilo&#44; mostaza nitrogenada&#44; ciclofosfamida&#44; temozolamida&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Inhibidores topoisomerasa &#40;etop&#243;sido&#44; doxurribicina pegilada&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Inhibidores histona deacetilasa &#40;vorinostat&#44; romidepsina&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">CHOP y CHOP-<span class="elsevierStyleItalic">like</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>TPMO&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Aut&#243;logo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Alog&#233;nico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Alog&#233;nico no mieloablativo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab884197.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Tratamientos en el SS</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "tbl0015"
        "etiqueta" => "Tabla 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">H&#58; hombre&#59; LNH&#58; linfoma no Hodgkin&#59; m&#58; meses&#59; M&#58; mujer&#44; NR&#58; no respuesta&#44; PE&#58; progresi&#243;n de la enfermedad&#59; RC&#58; remisi&#243;n completa&#59; RP&#58; respuesta parcial&#44; Sd&#58; s&#237;ndrome&#59; S&#58; semanas&#59; &#40;X&#175;&#41;&#58; mediana&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Sexo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Edad&#40;a&#241;os&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Duraci&#243;ndeltratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Iniciode larespuesta&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Respuesta Cut&#225;nea<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Respuesta sangu&#237;nea<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a>&#40;c&#233;lulas de S&#233;zary&#47;&#956;l y &#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Respuesta global&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Duraci&#243;n de la respuesta&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Complicaciones&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Evoluci&#243;n y tiempo de seguimiento tras inicio del tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">M&#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">57&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4 S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RCPre-tto&#8594;1&#46;050 &#40;7&#37;&#41;Post-tto&#8594;0 &#40;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">66<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RC67<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">H&#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">65&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RCPre-tto&#8594;9&#46;530 &#40;32&#37;&#41;Post-tto&#8594;147 &#40;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Sd liberaci&#243;n citocinasReactivaci&#243;n CMVNeumon&#237;a neumoc&#243;cica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top"><span class="elsevierStyleItalic">&#201;xitus</span> por LNH alto grado24<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">M&#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">85&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RPPre-tto&#8594;1&#46;215 &#40;12&#37;&#41;Post-tto&#8594;379 &#40;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Retratamiento a las 4<span class="elsevierStyleHsp" style=""></span>S sin mejor&#237;a&#46;Actualmente leukeran-prednisona27<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">H&#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">75&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RCPre-tto&#8594;554 &#40;4&#37;&#41;<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">c</span></a>Post-tto&#8594;0 &#40;0&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">15<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Sd liberaci&#243;n citocinasReactivaci&#243;n CMV&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Actualmente fotof&#233;resis32<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">M&#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">57&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RCPre-tto&#8594;1&#46;342 &#40;8&#37;&#41;Post-tto&#8594;55 &#40;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">NR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Sd liberaci&#243;n citocinas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Trasplante alog&#233;nico de m&#233;dula &#243;sea20<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">&#40;X&#175;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">65&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="" valign="top">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab884195.png"
              ]
            ]
          ]
          "notaPie" => array:3 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">RC&#58; 100&#37; del aclaramiento de las lesiones&#44; RP&#58; 50-99&#37; del aclaramiento de las lesiones iniciales sin nuevos tumores &#40;T3&#41; en pacientes con T1&#44; T2 o T4&#44; PE<span class="elsevierStyleHsp" style=""></span>&#8805;<span class="elsevierStyleHsp" style=""></span>25&#37; de incremento de la enfermedad cut&#225;nea o nuevos tumores &#40;T3&#41; en pacientes con T1&#44; T2 o T4 o p&#233;rdida de respuesta en pacientes con respuesta completa o respuesta parcial<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">2</span></a>&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">RC&#58; B<span class="elsevierStyleInf">0</span> y RP<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>50&#37; de reducci&#243;n de la carga tumoral sangu&#237;nea inicial<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">2</span></a>&#46;</p>"
            ]
            2 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "c"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">El caso 4 presentaba &#60;<span class="elsevierStyleHsp" style=""></span>1000 c&#233;lulas de Sez&#225;ry&#44; sin embargo ten&#237;a un cociente CD4&#47;CD8<span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>10&#44;por lo que se consider&#243; un estadio IVA<span class="elsevierStyleInf">1</span> como el resto&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Nuestra serie de 5 casos de SS tratados con alemtuzumab</p>"
        ]
      ]
      4 => array:7 [
        "identificador" => "tbl0020"
        "etiqueta" => "Tabla 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">CMV&#58; citomegalovirus&#59; EE&#58; enfermedad estable&#59; FOD&#58; fiebre de origen desconocido&#59; IAM&#58; infarto agudo de miocardio&#59; ICC&#58; insuficiencia card&#237;aca congestiva&#59; iv&#58; intravenosa&#59; LCCB&#58; linfoma cut&#225;neo de c&#233;lula B&#59; LCCT&#58; linfomas cut&#225;neos de c&#233;lulas T&#59; LCCT-L&#58; linfomas cut&#225;neos de c&#233;lulas T leucemizados&#59; LCT perif&#233;ricos&#58; linfomas de c&#233;lulas T perif&#233;ricos&#59; LNH&#58; linfoma no Hodgkin&#59; MRSA&#58; <span class="elsevierStyleItalic">Staphilococcus aureus</span> meticil&#237;n resistente&#59; PE&#58; progresi&#243;n de la enfermedad&#59; RC&#58; respuesta completa&#59; RG&#58; respuesta global&#59; RP&#58; respuesta parcial&#59; sc&#58; subcut&#225;nea&#59; tbc&#58; tuberculosis&#59; VEB&#58; virus Epstein Barr&#59; VHS&#58; virus herpes simple&#59; VVZ&#58; virus varicela z&#243;ster&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Series&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">N&#46;&#176; de pacientes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Pauta de alemtuzumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Duraci&#243;n del tratamiento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Respuesta cl&#237;nica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Duraci&#243;n de la respuesta &#40;mediana&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th><th class="td" title="table-head  " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Complicaciones graves&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Lundin J et al&#46;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">7</span></a> &#40;1998&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">50 LNH bajo grado&#40;8<span class="elsevierStyleHsp" style=""></span>MF&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30<span class="elsevierStyleHsp" style=""></span>mg v&#237;a iv 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6-12<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 20&#37;MF&#58; RG&#58; 50&#37;&#44; 2<span class="elsevierStyleHsp" style=""></span>RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Infecciones oportunistas &#40;7&#41;&#44; sepsis &#40;9&#41;&#44; neutropenia grado <span class="elsevierStyleSmallCaps">iv</span> &#40;14&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Lundin J et al&#46;<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">8</span></a> &#40;2003&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">22<span class="elsevierStyleHsp" style=""></span>MF&#47;SS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30 mg v&#237;a iv 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 55&#37;7<span class="elsevierStyleHsp" style=""></span>RC&#44; 5<span class="elsevierStyleHsp" style=""></span>RP&#44; 3<span class="elsevierStyleHsp" style=""></span>EE&#44; 7<span class="elsevierStyleHsp" style=""></span>PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Reactivaci&#243;n CMV &#40;4&#41;&#44; FOD &#40;3&#41;&#44; VHS generalizado &#40;1&#41;&#44; aspergilosis pulmonar &#40;1&#41;&#44; <span class="elsevierStyleItalic">Mycobacterium pneumoniae</span> &#40;1&#41;&#44; neutropenia febril &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Kennedy GA et al&#46;<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">10</span></a> &#40;2003&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5<span class="elsevierStyleHsp" style=""></span>MF&#47;2<span class="elsevierStyleHsp" style=""></span>SS1<span class="elsevierStyleHsp" style=""></span>MF transformada a c&#233;lula grande&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30 mg v&#237;a iv 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3-13<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 38&#37;3<span class="elsevierStyleHsp" style=""></span>RP&#44; 2<span class="elsevierStyleHsp" style=""></span>EE&#44; 3<span class="elsevierStyleHsp" style=""></span>PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Menos de 3<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Pancitopenia grado <span class="elsevierStyleSmallCaps">iv</span> con sepsis &#40;2&#41;&#44; MRSA cut&#225;neo y VHS oral &#40;1&#41;&#44; bronquiolitis viral &#40;1&#41;&#44; VVZ cut&#225;neo &#40;1&#41;&#44; CMV &#40;1&#41;&#44; osteomielitis por <span class="elsevierStyleItalic">Pseudomona</span> e infecci&#243;n <span class="elsevierStyleItalic">Parvovirus</span> &#40;1&#41;&#44; sepsis por <span class="elsevierStyleItalic">Klebsiella</span> &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Ferrajoli et al&#46; <a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">11</span></a> &#40;2003&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6<span class="elsevierStyleHsp" style=""></span>LCCT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30 mg v&#237;a iv 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4-12<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2<span class="elsevierStyleHsp" style=""></span>RP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Capalbo S et al&#46;<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">12</span></a> &#40;2003&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1<span class="elsevierStyleHsp" style=""></span>MF&#47;2<span class="elsevierStyleHsp" style=""></span>SS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30 mg v&#237;a iv 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#44;6 y 12<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1<span class="elsevierStyleHsp" style=""></span>RC&#44; 1<span class="elsevierStyleHsp" style=""></span>RP&#44; 1 <span class="elsevierStyleItalic">&#233;xitus</span> &#40;IAM&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">11<span class="elsevierStyleHsp" style=""></span>m3<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Lenihan DJ et al&#46;<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">13</span></a> &#40;2004&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5<span class="elsevierStyleHsp" style=""></span>SS y 3<span class="elsevierStyleHsp" style=""></span>MF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30 mg v&#237;a iv 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8&#44;5<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3<span class="elsevierStyleHsp" style=""></span>RP&#44; 2<span class="elsevierStyleHsp" style=""></span>EE&#44; 3<span class="elsevierStyleHsp" style=""></span>PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Eventos cardiovasculares &#40;5&#41;&#58; ICC&#47;arritmiasDos exitus por infecciones no especificadasUna neumon&#237;a <span class="elsevierStyleItalic">Legionella pneumoniae</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Zinzani et al&#46; <a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">14</span></a> &#40;2005&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4<span class="elsevierStyleHsp" style=""></span>MF6<span class="elsevierStyleHsp" style=""></span>LCT perif&#233;ricos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">4<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3<span class="elsevierStyleHsp" style=""></span>RP &#40;MF&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Reactivaci&#243;n CMV &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Bernengo et al&#46;<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">4</span></a> &#40;2007&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">14<span class="elsevierStyleHsp" style=""></span>SS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10-15<span class="elsevierStyleHsp" style=""></span>mg v&#237;a sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">1<span class="elsevierStyleHsp" style=""></span>RC&#44; 11<span class="elsevierStyleHsp" style=""></span>RP&#44; 2<span class="elsevierStyleHsp" style=""></span>EE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Infecciones en pacientes tratados con 15<span class="elsevierStyleHsp" style=""></span>mg&#58;Sepsis estafiloc&#243;cica &#40;1&#41;Reactivaci&#243;n CMV subcl&#237;nica &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Alinari et al&#46;<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">15</span></a> &#40;2007&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5<span class="elsevierStyleHsp" style=""></span>SS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30<span class="elsevierStyleHsp" style=""></span>mg v&#237;a sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5-9<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 100&#37;5<span class="elsevierStyleHsp" style=""></span>RC&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Reactivaci&#243;n CMV asintom&#225;tica &#40;2&#41;&#44; reactivaci&#243;n VEB &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Querfeld et al&#46; <a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">16</span></a> &#40;2009&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">17<span class="elsevierStyleHsp" style=""></span>SS2<span class="elsevierStyleHsp" style=""></span>MF eritrod&#233;rmicas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30<span class="elsevierStyleHsp" style=""></span>mg v&#237;a iv y sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 84&#37;9<span class="elsevierStyleHsp" style=""></span>RC&#44; 7<span class="elsevierStyleHsp" style=""></span>RP&#44; 3<span class="elsevierStyleHsp" style=""></span>PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">&#201;xitus por pancitopenia grado <span class="elsevierStyleSmallCaps">iv</span> &#40;1&#41;Absceso cervical &#40;1&#41;&#44; sepsis por MRSA &#40;1&#41;&#44; herpes z&#243;ster &#40;1&#41;&#44; infecci&#243;n del cat&#233;ter central &#40;1&#41;&#44; neutropenia febril &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Clark et al&#46;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">6</span></a> &#40;2012&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">18<span class="elsevierStyleHsp" style=""></span>LCCT-L&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">6<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 89&#37;9<span class="elsevierStyleHsp" style=""></span>RC&#44; 7<span class="elsevierStyleHsp" style=""></span>RP&#44; 2<span class="elsevierStyleHsp" style=""></span>PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Reactivaci&#243;n CMV &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">De Masson et al&#46;<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">9</span></a> &#40;2014&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">23<span class="elsevierStyleHsp" style=""></span>SS&#47;16<span class="elsevierStyleHsp" style=""></span>MF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">30<span class="elsevierStyleHsp" style=""></span>mg v&#237;a iv y sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">12<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">RG&#58; 51&#37;&#40;70&#37; SS&#44; 25&#37; MF&#41;7<span class="elsevierStyleHsp" style=""></span>RC &#40;6<span class="elsevierStyleHsp" style=""></span>SS&#44; 1<span class="elsevierStyleHsp" style=""></span>MF&#41;13<span class="elsevierStyleHsp" style=""></span>RP &#40;10<span class="elsevierStyleHsp" style=""></span>SS&#44; 3<span class="elsevierStyleHsp" style=""></span>MF&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">3&#44;4<span class="elsevierStyleHsp" style=""></span>m6ptes <span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>24<span class="elsevierStyleHsp" style=""></span>m&#40;5<span class="elsevierStyleHsp" style=""></span>SS&#44; 1<span class="elsevierStyleHsp" style=""></span>MF&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Viremia CMV &#40;10&#41;&#44; tbc &#40;2&#41;&#44; infecci&#243;n cut&#225;nea por <span class="elsevierStyleItalic">Mycobacterium chelonae</span> &#40;1&#41;&#44; infecci&#243;n bacteriana &#40;5&#41;&#44; toxoplasmosis &#40;1&#41;&#44; aspergilosis &#40;1&#41;&#44; neumon&#237;a &#40;7&#41;&#44; citopenias grado 3 &#40;10&#41;&#44; exitus &#40;2&#41;&#44; transformaci&#243;n a LCCT c&#233;lula grande &#40;5&#41;&#44; LCCB grande &#40;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Watanabe et al&#46;<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">17</span></a> &#40;2014&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">17<span class="elsevierStyleHsp" style=""></span>SS&#47;6<span class="elsevierStyleHsp" style=""></span>MF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">SS&#58; 13 RC&#44; 4 RPMF&#58; 1 RC tras <span class="elsevierStyleItalic">electron beam</span>&#44; 5 PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">ND&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry  " align="left" valign="top">Nuestra serie&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">5<span class="elsevierStyleHsp" style=""></span>SS&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>mg v&#237;a sc 3 d&#237;as&#47;semana&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">8<span class="elsevierStyleHsp" style=""></span>S&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">2 RC&#44;2 RP&#44; 1 PE&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">13<span class="elsevierStyleHsp" style=""></span>m&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="table-entry  " align="left" valign="top">Neumon&#237;a neumoc&#243;cica &#40;1&#41;Reactivaci&#243;n CMV asintom&#225;tica &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab884198.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "es" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">Series publicadas de pacientes con SS&#47;MF tratados con alemtuzumab</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliograf&#237;a"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:18 [
            0 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primary cutaneous T-cell lymphoma &#40;mycosis fungoides and S&#233;zary syndrome&#41;&#58; Part I diagnosis&#58; Clinical and histopathologic features and new molecular and biologic markers"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46;I&#46; Jawed"
                            1 => "P&#46;L&#46; Myskowski"
                            2 => "S&#46; Horwitz"
                            3 => "A&#46; Moskowitz"
                            4 => "C&#46; Querfeld"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2014"
                        "volumen" => "70"
                        "paginaInicial" => "205e1"
                        "paginaFinal" => "2216e"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical end points and response criteria in mycosis fungoides and S&#233;zary syndrome&#58; A consensus statement of the International Society for Cutaneous Lymphomas&#44; the United States Cutaneous Lymphoma Consortium&#44; and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46;A&#46; Olsen"
                            1 => "S&#46; Whittaker"
                            2 => "Y&#46;H&#46; Kim"
                            3 => "M&#46; Duvic"
                            4 => "H&#46;M&#46; Prince"
                            5 => "S&#46;R&#46; Lessin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/JCO.2010.32.0630"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "2011"
                        "volumen" => "29"
                        "paginaInicial" => "2598"
                        "paginaFinal" => "2607"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21576639"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Primary cutaneous T-cell lymphoma &#40;mycosis fungoides and S&#233;zary syndrome&#41;&#58; Part II prognosis&#44; management&#44; and future directions"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46;I&#46; Jawed"
                            1 => "P&#46;L&#46; Myskowski"
                            2 => "S&#46; Horwitz"
                            3 => "A&#46; Moskowitz"
                            4 => "C&#46; Querfeld"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Am Acad Dermatol"
                        "fecha" => "2014"
                        "volumen" => "70"
                        "paginaInicial" => "223e1"
                        "paginaFinal" => "223e17"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome&#58; Clinical and immunologic findings in 14 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;G&#46; Bernengo"
                            1 => "P&#46; Quaglino"
                            2 => "A&#46; Comessatti"
                            3 => "M&#46; Ortoncelli"
                            4 => "M&#46; Novelli"
                            5 => "F&#46; Lisa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Haematologica"
                        "fecha" => "2007"
                        "volumen" => "92"
                        "paginaInicial" => "784"
                        "paginaFinal" => "794"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17550851"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Actualizaci&#243;n terap&#233;utica en linfomas cut&#225;neos"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R&#46;M&#46; Izu-Belloso"
                            1 => "J&#46;C&#46; Garcia-Ruiz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2012.01.011"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2012"
                        "volumen" => "103"
                        "paginaInicial" => "694"
                        "paginaFinal" => "707"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22575363"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "R&#46;A&#46; Clark"
                            1 => "R&#46; Watanabe"
                            2 => "J&#46;E&#46; Teague"
                            3 => "C&#46; Schlapbach"
                            4 => "M&#46;C&#46; Tawa"
                            5 => "N&#46; Adams"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Sci Transl Med"
                        "fecha" => "2012"
                        "volumen" => "4"
                        "paginaInicial" => "117ra117"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin&#39;s lymphomas&#58; A phase II multicenter study European Study Group of CAMPATH-1H treatment in low-grade non-Hodgkin&#39;s lymphoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Lundin"
                            1 => "A&#46; Osterborg"
                            2 => "G&#46; Brittinger"
                            3 => "D&#46; Crowther"
                            4 => "H&#46; Dombret"
                            5 => "A&#46; Engert"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1200/jco.1998.16.10.3257"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Oncol"
                        "fecha" => "1998"
                        "volumen" => "16"
                        "paginaInicial" => "3257"
                        "paginaFinal" => "3263"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9779699"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0130"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Phase 2 study of alemtuzumab &#40;anti-CD52 monoclonal antibody&#41; in patients with advanced mycosis fungoides&#47;S&#233;zary syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46; Lundin"
                            1 => "H&#46; Hagberg"
                            2 => "R&#46; Repp"
                            3 => "E&#46; Cavallin-St&#229;hl"
                            4 => "S&#46; Fred&#233;n"
                            5 => "G&#46; Juliusson"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2002-09-2802"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2003"
                        "volumen" => "101"
                        "paginaInicial" => "4267"
                        "paginaFinal" => "4272"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12543862"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0135"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; De Masson"
                            1 => "P&#46; Guitera"
                            2 => "P&#46; Brice"
                            3 => "I&#46; Moulonguet"
                            4 => "F&#46; Mouly"
                            5 => "J&#46;D&#46; Bouaziz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.12690"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2014"
                        "volumen" => "170"
                        "paginaInicial" => "720"
                        "paginaFinal" => "724"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24438061"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0140"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of patients with advanced mycosis fungoides and S&#233;zary syndrome with alemtuzumab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46;A&#46; Kennedy"
                            1 => "J&#46;F&#46; Seymour"
                            2 => "M&#46; Wolf"
                            3 => "H&#46; Januszewicz"
                            4 => "J&#46; Davison"
                            5 => "C&#46; McCormack"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Eur J Haematol"
                        "fecha" => "2003"
                        "volumen" => "71"
                        "paginaInicial" => "250"
                        "paginaFinal" => "256"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12950233"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0145"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Phase II study of alemtuzumab in chronic lymphoproliferative disorders"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Ferrajoli"
                            1 => "S&#46;M&#46; O&#8217;Brien"
                            2 => "J&#46;E&#46; Cortes"
                            3 => "F&#46;J&#46; Giles"
                            4 => "D&#46;A&#46; Thomas"
                            5 => "S&#46; Faderl"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/cncr.11551"
                      "Revista" => array:6 [
                        "tituloSerie" => "Cancer"
                        "fecha" => "2003"
                        "volumen" => "98"
                        "paginaInicial" => "773"
                        "paginaFinal" => "778"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12910522"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Mycosis fungoides&#47;S&#233;zary syndrome&#58; A report of three cases treated with Campath-1H as salvage treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Capalbo"
                            1 => "M&#46; Delia"
                            2 => "M&#46; Dargenio"
                            3 => "A&#46; Liso"
                            4 => "D&#46; Diomede"
                            5 => "L&#46; Garofalo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1385/MO:20:4:389"
                      "Revista" => array:6 [
                        "tituloSerie" => "Med Oncol"
                        "fecha" => "2003"
                        "volumen" => "20"
                        "paginaInicial" => "389"
                        "paginaFinal" => "396"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14716037"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cardiac toxicity of alemtuzumab in patients with mycosis fungoides&#47;S&#233;zary syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "D&#46;J&#46; Lenihan"
                            1 => "A&#46;J&#46; Alencar"
                            2 => "D&#46; Yang"
                            3 => "R&#46; Kurzrock"
                            4 => "M&#46;J&#46; Keating"
                            5 => "M&#46; Duvic"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1182/blood-2003-07-2345"
                      "Revista" => array:6 [
                        "tituloSerie" => "Blood"
                        "fecha" => "2004"
                        "volumen" => "104"
                        "paginaInicial" => "655"
                        "paginaFinal" => "658"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15073032"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "P&#46;L&#46; Zinzani"
                            1 => "L&#46; Alinari"
                            2 => "M&#46; Tani"
                            3 => "M&#46; Fina"
                            4 => "S&#46; Pileri"
                            5 => "M&#46; Baccarani"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Haematologica"
                        "fecha" => "2005"
                        "volumen" => "90"
                        "paginaInicial" => "702"
                        "paginaFinal" => "703"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15921394"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Subcutaneous alemtuzumab for S&#233;zary syndrome in the very elderly"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "L&#46; Alinari"
                            1 => "L&#46; Geskin"
                            2 => "T&#46; Grady"
                            3 => "R&#46;A&#46; Baiocchi"
                            4 => "M&#46;A&#46; Bechtel"
                            5 => "P&#46; Porcu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.leukres.2007.11.009"
                      "Revista" => array:6 [
                        "tituloSerie" => "Leuk Res"
                        "fecha" => "2008"
                        "volumen" => "32"
                        "paginaInicial" => "1299"
                        "paginaFinal" => "1303"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18096224"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma&#58; A single institution experience from the Robert H Lurie Comprehensive Cancer Center"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46; Querfeld"
                            1 => "N&#46; Mehta"
                            2 => "S&#46;T&#46; Rosen"
                            3 => "J&#46; Guitart"
                            4 => "A&#46; Rademaker"
                            5 => "P&#46; Gerami"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3109/10428190903216770"
                      "Revista" => array:6 [
                        "tituloSerie" => "Leuk Lymphoma"
                        "fecha" => "2009"
                        "volumen" => "50"
                        "paginaInicial" => "1969"
                        "paginaFinal" => "1976"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19860617"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma&#58; Diffuse erythema as a positive predictor of complete remission"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "R&#46; Watanabe"
                            1 => "J&#46;E&#46; Teague"
                            2 => "D&#46;C&#46; Fisher"
                            3 => "T&#46;S&#46; Kupper"
                            4 => "R&#46;A&#46; Clark"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2013.10099"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol"
                        "fecha" => "2014"
                        "volumen" => "150"
                        "paginaInicial" => "776"
                        "paginaFinal" => "779"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24760312"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous hemophagocytosis after alemtuzumab injection in a patient with S&#233;zary syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46;I&#46; Jawed"
                            1 => "K&#46; Busam"
                            2 => "X&#46; Wang"
                            3 => "S&#46; Horwitz"
                            4 => "C&#46; Querfeld"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamadermatol.2013.10615"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Dermatol"
                        "fecha" => "2014"
                        "volumen" => "150"
                        "paginaInicial" => "1021"
                        "paginaFinal" => "1023"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25029560"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00017310/0000010600000007/v1_201509041239/S0001731015001477/v1_201509041239/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "24962"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "e-Casos cl&#237;nicos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000010600000007/v1_201509041239/S0001731015001477/v1_201509041239/es/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731015001477?idApp=UINPBA000044"
]
Información del artículo
ISSN: 00017310
Idioma original: Español
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 12 8 20
2024 Octubre 130 45 175
2024 Septiembre 87 25 112
2024 Agosto 122 47 169
2024 Julio 110 29 139
2024 Junio 157 32 189
2024 Mayo 104 43 147
2024 Abril 95 19 114
2024 Marzo 82 28 110
2024 Febrero 88 25 113
2024 Enero 123 19 142
2023 Diciembre 95 18 113
2023 Noviembre 140 22 162
2023 Octubre 100 21 121
2023 Septiembre 106 37 143
2023 Agosto 105 15 120
2023 Julio 121 36 157
2023 Junio 132 43 175
2023 Mayo 142 58 200
2023 Abril 102 29 131
2023 Marzo 99 49 148
2023 Febrero 89 23 112
2023 Enero 72 27 99
2022 Diciembre 112 31 143
2022 Noviembre 108 42 150
2022 Octubre 153 38 191
2022 Septiembre 76 58 134
2022 Agosto 122 56 178
2022 Julio 111 57 168
2022 Junio 110 39 149
2022 Mayo 110 45 155
2022 Abril 127 50 177
2022 Marzo 125 57 182
2022 Febrero 78 28 106
2022 Enero 86 57 143
2021 Diciembre 86 40 126
2021 Noviembre 75 44 119
2021 Octubre 95 44 139
2021 Septiembre 67 29 96
2021 Agosto 86 24 110
2021 Julio 60 28 88
2021 Junio 94 37 131
2021 Mayo 85 31 116
2021 Abril 141 59 200
2021 Marzo 124 35 159
2021 Febrero 104 33 137
2021 Enero 95 27 122
2020 Diciembre 69 28 97
2020 Noviembre 51 30 81
2020 Octubre 68 30 98
2020 Septiembre 57 22 79
2020 Agosto 60 37 97
2020 Julio 53 17 70
2020 Junio 80 39 119
2020 Mayo 99 25 124
2020 Abril 67 26 93
2020 Marzo 61 27 88
2020 Febrero 13 8 21
2020 Enero 85 2 87
2019 Diciembre 8 11 19
2019 Noviembre 4 6 10
2019 Octubre 6 12 18
2019 Septiembre 8 13 21
2019 Agosto 4 11 15
2019 Julio 2 20 22
2019 Junio 6 21 27
2019 Mayo 5 27 32
2019 Abril 3 5 8
2019 Marzo 3 5 8
2019 Febrero 2 4 6
2019 Enero 3 2 5
2018 Diciembre 2 3 5
2018 Noviembre 3 5 8
2018 Octubre 2 1 3
2018 Septiembre 6 3 9
2018 Agosto 0 10 10
2018 Julio 1 13 14
2018 Junio 0 10 10
2018 Mayo 0 9 9
2018 Abril 1 2 3
2018 Febrero 26 6 32
2018 Enero 30 8 38
2017 Diciembre 26 8 34
2017 Noviembre 47 9 56
2017 Octubre 32 9 41
2017 Septiembre 22 18 40
2017 Agosto 9 2 11
2017 Julio 2 1 3
2017 Junio 13 0 13
2017 Mayo 6 1 7
2017 Abril 7 0 7
2017 Marzo 2 1 3
2017 Febrero 2 2 4
2017 Enero 7 1 8
2016 Diciembre 10 5 15
2016 Noviembre 11 15 26
2016 Octubre 11 14 25
2016 Septiembre 0 18 18
2016 Agosto 0 4 4
2016 Julio 12 6 18
2016 Junio 24 1 25
2016 Mayo 20 3 23
2016 Abril 13 1 14
2016 Marzo 10 11 21
2016 Febrero 0 3 3
2016 Enero 0 1 1
2015 Diciembre 0 3 3
2015 Noviembre 0 1 1
2015 Octubre 0 7 7
2015 Septiembre 0 10 10
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Actas Dermo-Sifiliográficas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?